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ABSTRACT
Non-small cell lung cancer (NSCLC) is the leading cause of cancer death worldwide with
a low 5-year survival rate of only around 21%. This low 5-year survival rate is due to two main
reasons. First, NSCLC is often diagnosed at the later stages when it has already metastasized.
Second, NSCLC is an incredibly diverse, heterogenous disease making it very hard to target the
true molecular oncogenic drivers. New targets for personalized therapeutics are needed based on
the expression status of each individual lung cancer tumor.
One way of looking for these new therapeutics is to begin by identifying the
oncogenotype status. Two common oncogenotypes in NSCLC which are considered nonactionable, or non-targetable, are mutations in the KRAS or TP53 genes. To target these
genotypes, we used transcriptomics and bioinformatics to analyze NSCLC cell lines based on
their KRAS or TP53 oncogenotype status for potential alternative splicing events identified via
differential exon usage.
Further investigation into these differentially regulated alternatively spliced genes
revealed a novel intergenic non-coding RNA which is dysregulated in some NSCLC cell lines.
While the precise mechanism behind CDLINC’s CDKN2A dysregulation mechanism is
unknown, our data strongly suggest that it is acting as ceRNA to sponge miRNAs thus indirectly
suppressing CDKN2A expression. Future directions for this research include identifying
CDLINC binding partners and clarifying the mechanisms responsible for its cancer-linked
function. In conclusion, the targetability of CDLINC by RNAi suggests it may act as a candidate
for targeted therapeutics in the future of NSCLC treatment.

viii

CHAPTER ONE: INTRODUCTION

Non-Small Cell Lung Cancer (NSCLC)
Lung cancer is the second leading cancer in both men and women in the United States [13]. In 2020 13% of all new cancer cases diagnosed will be lung cancer, an estimated 228,820
cases in the United States (US) and more than 2 million cases worldwide [4]. It is second only to
prostate cancer in men and breast cancer in women. That means about 1 in 15 men or 1 in 17
women in the US will develop lung cancer in his or her lifetime [5]. Although lung cancer is
only the second leading cause of cancer in either sex, it is the deadliest type of cancer for both
sexes [5]. Everyday over 400 Americans will die of lung cancer [6, 7]. Lung cancer will account
for about 23% of all US cancer deaths, or an estimated 135,720 deaths in 2020. Worldwide it
will be responsible for more than 1.6 million deaths [5]. Prostate and breast cancer are predicted
to account for 10% and 15% respectively. This is due to the low 5-year survival rate for lung
cancer, which currently is about 21%. Prostate cancer, on the other hand, has a 99% 5-year
survival rate and breast cancer has a 91% 5-year survival rate.
In the US ~85% of all lung cancer cases diagnosed are non-small cell lung cancer
(NSCLC) cases [8]. NSCLC has 3 main histological subtypes: the more common lung
adenocarcinomas (LUAD) and squamous cell carcinomas (LUSC) [9] as well as large cell
carcinomas. LUAD are formed in cells that secrete things, typically the cuboidal mucus secreting
type II pneumocytes which line the surface of the alveoli. LUSC are derived from flat squamous
cells which line the airways. Large cell carcinomas are undifferentiated tumors which tend to
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grow and spread quickly. These large cell carcinomas are also notoriously difficult to treat due to
this. Both NSCLC and small cell lung cancer (SCLC) are associated with smoking, but LUAD
tumors are the most prevalent type of lung cancer formed in cancer patients who have no history
of smoking [10].
Five of the most common treatment options for NSCLC include: surgery, radiation
therapy, chemotherapy, targeted therapy and immunotherapy [11]. The therapeutic option chosen
depends largely on the stage of the cancer [8]. Stage 0 and stage I tumors are typically treated
with surgery. Some stage I and most stage II and stage III cancers are treated with more
aggressive surgery followed by adjuvant radiation and/or chemotherapy typically with a
combination of drugs such as cisplatin or carboplatin with another chemotherapeutic drug. When
the patient is not heathy enough for surgery, chemoradiation therapy is often indicated. Some
stage III cancers may be treated with immunotherapy drugs when other options are not available.
Due to the nature of stage IV cancers, treatment options largely depend on the extent of
metastasis and the patient’s overall health status. When the NSCLC has metastasized widely
throughout the body, tumors are likely to be tested for common driver mutations, such as those
shown in Table 1, in order to treat with targeted therapeutics [12-17].
Although some targeted therapeutics are available, current drug therapies struggle to treat
this common and high mortality cancer due to its heterogeneous genomic and transcriptomic
profiles [18-34]. Very few patients with NSCLC are eligible for screening for personalized
therapeutics; in most cases, the molecular driver of the tumor remains unknown [35]. Therefore,
better personalization of therapeutic regimens now requires a multi-omics approach.
Personalized targeted therapeutics based on molecular markers is a quickly progressing field in
lung cancer research, yet many lung cancers are still lacking effective treatment options [34, 36-
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45]. Table 1, on the following page, shows the mutation status of common molecular markers
for LUAD and LUSC NSCLC.

Spliceomics
The central dogma of biology can be stated simply in that DNA makes RNA which then
makes proteins. Simplistically, this dogma maintains that the ~25,000 genes in the human
genome make the more than 100,000 proteins in the human proteome [46]. This is where the
transcriptome comes in. As shown in figure 1, transcriptomics is the study of the transcriptome.
The human transcriptome consists of more than 1,000,000 RNA transcripts. It is these transcripts
that are responsible for the large diversity of proteins made from so few genes. In fact, protein
coding genes account for less than 3% of the human genome [47, 48]. Spliceomics, the study of
global changes in alternative splicing, is responsible for much of the complexity achieved in the
human transcriptome. Alternative splicing occurs in a variety of ways including exon skipping,
mutually exclusive exons, alternative polyadenylation, intron retention, alternative 5’ or 3’ splice
sites and alternative promoters.

Non-Coding RNAs (ncRNAs)
Over 80% of the human transcriptome is comprised of non-coding RNAs (ncRNAs) [51].
This category can be further broken into two categories: small non-coding RNAs and long noncoding RNAs. Small non-coding RNAs, also known as microRNAs (miRNAs) are ncRNAs less
than 200 nucleotides (nt) in length which are transcribed by RNA polymerase II, still undergo
endogenous processing by endonucleases and are well conserved. There are over 2,000 known
miRNAs. Long non-coding RNAs (lncRNAs) on the other hand are ncRNA transcripts greater
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Table 1: Prevalence of common NSCLC molecular markers
Cellular Process

Molecular
Marker

Status in
Cancer

LUAD
Prevalence

LUSC
Prevalence

Proliferation, cell survival,
translation

EGFR

Activated

27%

<9%

ERBB2/3

Activated

3%

2-4%

MET

Activated

7%

*

FGFR1, 2, 3

Activated

*

7%, 3%, 2%

ALK

Activated

<8%

*

Oxidative stress response

Proliferation, cell survival

Cell cycle progression

RET

Activated

1%

*

ROS

Activated

2%

*

PTEN

Inactivated

3%

15%

PIK3R1

Inactivated

<1%

*

PI3CA

Activated

4%

16%

KRAS

Activated

32%

3%

HRAS

Activated

<1%

3%

NRAS

Activated

<1%

<1%

RIT1

Activated

2%

*

RASA

Inactivated

*

4%

NF1

Inactivated

11%

11%

STK11

Activated

17%

2%

AKT1

Activated

1%

<1%

AKT2

Activated

*

4%

AKT3

Activated

*

16%

BRAF

Activated

7%

4%

AMPK

Activated

*

*

TSC1/2

Inactivated

3%

3%

MTOR

Activated

*

*

MAP2K1

Activated

<1%

<1%

KEAP1

Inactivated

19%

12%

CUL3

Inactivated

<1%

7%

NFE2L2

Activated

3%

19%

MDM2

Activated

8%

*

ATM

Inactivated

9%

*

TP53

Inactivated

46%

90%

CDKN2A

Inactivated

43%

70%

CCND1

Activated

4%

*

CDK4

Activated

7%

*

CCNE4

Activated

3%

*

RB1

Inactivated

7%

7%

Modified from Box 1 of Herbst et al 2018 [49] with data from [20, 21, 35, 50]. * represents no data
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than 200 nt in length which are also transcribed by RNA polymerase II, mostly 5’-capped, often
polyadenylated and even spliced/alternatively spliced. These lncRNAs are typically poorly
conserved. There are more than 30,000 known lncRNAs in the human transcriptome.
The mechanisms of ncRNA functions are complex. Cellular functions regulated by
lncRNAs vary by cellular location [52]. In the nucleus, lncRNAs can regulate transcription and
splicing as well as act as enhancers and modify chromatin. In the cytoplasm, lncRNAs are used
for nuclear trafficking, mRNA stability, translational regulation and can even act as peptide
templates. An additional cytoplasmic function of lncRNAs is also to act as miRNA sponges.
Outside of the cell body lncRNAs can act as extracellular vesicles and stabilize lipoprotein
formation [53]. Many functions of lncRNAs are likely yet undiscovered as novel lncRNAs are
being continually published.

Non-Coding RNAs in Cancer
NcRNAs have emerged as key regulators in cancer [54, 55]. No type of cancer is exempt
from these molecules [34, 56-105] and lncRNAs and have a wide variety of biological effects in
cancer. The dysregulation of ncRNAs molecules have both diagnostic and therapeutic potential
for lung cancer [55, 106-126].

Cancer/Testis Antigens (CTAs)
A subset of lncRNAs in cancer are known as the Cancer/Testis Antigens (CTAs) [127,
128]. CTAs are lncRNAs that are endogenously highly expressed only in the testes and tend to
also be highly expressed in cancer suggesting an oncogenic role for them. These CTAs play roles

5

in cell cycle progression needed for spermatogenesis, a function that is then highjacked by
cancer to promote its own progression.

Public Health Relevance
About 1 in 15 men or 1 in 17 women will develop lung cancer in his or her lifetime.
Current drug therapies struggle to treat this common and high mortality cancer due to the
heterogeneous genomic and transcriptomic profiles. Hence, personalization of therapeutic
regimens requires a multi-omics approach. Using deep RNA sequencing data, we aim to identify
both alternative mRNA splicing and non-coding RNA pathways which might be able to serve as
targets for personalized drug therapies based on oncogenotype status of the tumor.

Hypothesis
Alternative splicing is causing altered transcript expression in non-small cell lung cancer
which plays key roles in tumor development and metastasis. CDLINC is a non-coding gene
consisting of alternatively spliced isoforms which when differentially expressed promote
NSCLC progression.

Significance
The alternative splicing regulated cellular proliferation mechanism of CDLINC may be a
basic cellular function which is hijacked by cancer for oncogenic purposes. CDLINC B+C
"knockdown" affects the CDKN2A pathway members. CDLINC B+C can inhibit the tumor
suppression functions of the CDKN2A pathway promoting the progression of NSCLC. This has
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implications for future treatment of tumors that have been sequenced to identify their best
therapeutic targets. CDLINC may be a valuable CTA target in NSCLC.

Research Aims
R1) Identify alternatively spliced genes in non-small cell lung cancer by bioinformatics.
R2) Determine if cancer related phenotypic changes exist due to these alternatively
spliced long intergenic non-coding gene CDLINC.

7

CHAPTER TWO: TRANSCRIPTOMIC ANALYSIS OF COMMON NSCLC CELL
LINES BY ONCOGENOTYPE

Abstract
Lung cancer is the leading cause of cancer deaths worldwide. In 2020, it is predicted to
cause and estimated 135,720 deaths in the US alone. Non-small cell lung cancer (NSCLC)
accounts for ~85% of all lung cancer cases. NSCLC is a very heterogenous disease which is
subject to frequent mutations leading to common molecular drivers of cancer. New molecular
targets are therefore needed to combat this deadly disease. Alternative splicing caused altered
transcript expression in non-small cell lung cancer which played key roles in tumor development
and metastasis. We used transcriptomics to bioinformatically identify potential new molecular
targets based on the oncogenotype status of the cancer, such as KRAS or TP53 mutations.

Introduction
Everyday over 400 Americans will die of lung cancer[6, 7]. Lung cancer will account for
about 23% of all US cancer deaths, or an estimated 135,720 deaths in 2020. Worldwide it will be
responsible for more than 1.6 million deaths [5]. In 2020 13% of all new cancer cases diagnosed
will be lung cancer, an estimated 228,820 cases in the United States (US) and more than 2
million cases worldwide [4]. In the US ~85% of all lung cancer cases diagnosed are non-small
cell lung cancer (NSCLC) cases [8]. NSCLC has 2 major histological subtypes: lung
adenocarcinomas (LUAD) and squamous cell carcinomas (LUSC) [9]. Both LUAD and LUSC
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cancers are prone to genetic mutations which are oncogenic drivers of cancer progression. Two
main molecular markers involved in both proliferation and cell survival and which are frequently
mutated in both LUAD and LUSC are KRAS (32% and 3% respectively) and TP53 (46% and
90% respectively) [20, 21, 35, 49, 50]. These two markers are non-actionable (non-targetable)
for targeted therapeutics and thus other means of treating them are necessary.
Transcriptomics is the complete set of RNA transcripts produced by a sample under
specific condition in a moment of time. This experimental approach provides insight into which
genes are being expressed during those precise conditions at that moment. The RNA is subject to
the unavoidable limitations of mRNA degradation. In order to obtain the full transcriptome
during library preparation, rRNA removal and not poly A selection is needed. This allows for
only the removal of rRNA and leaves the full transcriptome including ncRNA and regulatory
RNAs. Bioinformatic transcriptomic analysis can be used to identify differential gene
expression, differential exon usage, alternative splicing, circular RNAs, fusion genes, alternative
polyadenylation and viral RNA along with pathway analysis.
While differential gene expression can be used to identify dysregulated genes as potential
new targets for cancer therapeutics, looking past the genomics into the spliceomics of the
transcriptome provides more insight into targets. The canonical concept of splicing is that introns
are spliced out and exons are joined together forming an mRNA. If this was the only way that
mRNA was made, then a one-gene-one-protein model would be true. However, while there are
around 25,000 protein coding genes in the human genome, there are around 1,000,000 mRNAs
and over 100,000 proteins. This diversity in mRNAs is due to alternative splicing. Ways to
characterize alternative splicing include differential transcript expression and differential exon
usage. Both differential transcript expression and differential exon usage provide insights into
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the mechanism and function of the alternatively spliced transcripts. Identifying alternative
splicing events specific to oncogenotype status could provide new targets for cancer therapy. We
hypothesize that alternative splicing is causing altered transcript expression in genes specific to
either the KRAS or p53 (TP53) oncogenotype, which play key roles in tumor development and
metastasis.

Materials and Methods
Cancer Cell Lines and Media
The NSCLC cell lines A459, H838, H1299, H1792, human bronchial epithelial primary
cells (HBEpC) and immortalized human bronchial epithelial primary cells (HBEC) (purchased
from American Type Culture Collection, ATCC) were cultured in RPMI (H838, H1299, H1792;
Gibco), DMEM (A549; Gibco) or Airway Epithelial Cell Basal Medium and Bronchial
Epithelial Cell Growth Kit (HBEpC, HBEC; ATCC). All DMEM and RPMI was supplemented
with 10% fetal bovine serum (FBS, Gibco) and 1% penicillin/streptomycin (Gibco). Cell lines
were maintained in a 37°C incubator with 95% air and 5% CO2. Cells were maintained at less
than 90% confluency. Experiments were performed within the first 15 passages for all cell lines
except HBEpC which was limited to 5 passages. Before harvesting cell line samples for
sequencing, all samples were rested for 24 hours in serum and antibiotic free RPMI (Gibco) to
reduce the differential effects of serum growth factors on transcriptome expression.

RNA Isolation and Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR)
Total RNA was isolated by manufacturer’s protocol using the RNeasy Mini Kit (Qiagen)
and purified when necessary by RNA Clean & Concentrator (Zymo Research) following
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manufacturer’s protocol. RT-PCR was performed as described previously [46, 129] using High
Capacity cDNA Reverse Transcription Kit (Applied Biosystems) and RNase Out (Invitrogen).
RNA and cDNA were stored at –80°C.

Sequencing
A549, HBEpC, H838, H1299 and H1792 RNA was sent to the DNA Sequencing Center
at Brigham Young University for deep RNASeq. Library preparation included Ribo-Zero Gold
(Illumina) rRNA removal. Illumina HiSeq 2500 was used for 2 x 150 bp paired-end sequencing
to a depth of at least 100 million reads per sample.

Bioinformatic Analysis
Raw read files from sequencing were first checked for quality using FastQC [130] then
aligned using HISAT2 and assembled using Stringtie as described previously [131] to Hg38
(GENCODE 27 and Ensembl 91 [132, 133]). Differential expression was analyzed using
Ballgown [131]. Differential exon usage was performed using DEXSeq [134] as described by the
program publisher to identify exons with significant differential exon expression as defined as a
p-value of less than or equal to 0.05. DEXSeq uses a binomial distribution followed by
generalized linear models and a Benjamini-Hochberg p-value adjustment to obtain the final pvalue. Biostatistics analysis utilized either R or GraphPad Prism 5. Tests included t-test for
comparison between two samples and ANOVA with Tukey post-test for more than 2 samples.
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Quantitative Real Time Polymerase Chain Reaction (qRT-PCR)
Custom primers listed in table 2 were used for qRT-PCR as described previously [46].
Relative mRNA expression was normalized to either β Actin or internal levels (primer “ALL” in
the graphs, primer set 267053-E8-101bp from table 2) using ΔCT or ΔΔCT method.

Competitive Polymerase Chain Reaction (PCR)
Custom primers from table 3 were used for competitive PCR as described previously
[46]. Briefly, a thermocycler and the lid was heated to 95°C, initial denaturing was at 95°C for
60 seconds followed by 25 cycles of: denaturing at 95°C for 30 seconds, annealing at appropriate
temperature for each primer set for 30 seconds and extension at 72°C for 45 seconds. Final
extension was performed at 72°C for 5 minutes.

Results
The workflow shown in figure 1 was used to obtain all RNASeq (transcriptome
sequencing) data for this dissertation. Two types of HBEC cells were used in this study. The first
HBEC, HBEpC or primary cells (for bioinformatics), and the second HBEC, HBEC3KT (for in
vitro assays), cell lines were used as control non-cancerous cell lines. A549 and H1792 represent
NSCLC cell lines with KRAS mutations causing overexpression of this molecular driver. H1299
and H1792 represent NSCLC cell lines with TP53 inactivation mutations. H838 represents a
control cancer cell line that is wildtype (wt) for both KRAS and TP53 molecular drivers.
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Table 2: Custom primers designed for quantitative real time PCR
Gene

CDLINC

OXR1

RASSF4

Name

Sequence

Target

Direction

267053-E2-5-109bp FWD

GTC CAG CAG CAG GAA GAA A

CDLINC A

Forward

267053-E2-5-109bp REV

GTT TCC ACC CGC ACA CC

CDLINC A

Reverse

267053-E2-5-109bp PRB

/56-FAM/CGA TCT GTC /ZEN/TGA GGT TTC TTC C/3IABkFQ/

CDLINC A

Probe

267053-E2-8-147bp FWD
267053-E2-8-147bp REV

GAA GAA ACC TCA GAC AGA TCG
TGG GTT GCA GAG GAG AA

CDLINC B
CDLINC B

Forward
Reverse

267053-E2-8-147bp PRB

/56-FAM/TGT GCG GCG /ZEN/CAC ACA A/3IABkFQ/

CDLINC B

Probe

267053-E3-8-127bp FWD

GTC CAG CAG CAG GAA GAA A

CDLINC C

Forward

267053-E3-8-127bp REV

GCT CCT AAG CTT GGT TGT GT

CDLINC C

Reverse

267053-E3-8-127bp PRB

/56-FAM/AAC GGG AAA /ZEN/CCT CAG ACA GAT CGC /3IABkFQ/

CDLINC C

Probe

267053-E8-101bp FWD Set 2

AGT GAC ACG GAC AAG TTT CT

CDLINC E4

Forward

267053-E8-101bp REV Set 2

CAC CCG GGA CCA CAT TT

CDLINC E4

Reverse

267053-E8-101bp PRB Set 2

/56-FAM/AAC CCA ATG /ZEN/AGA GCT GCT GAC CA/3IABkFQ/

CDLINC E4

Probe

OXR1-E1-3-78bp FWD

CCT CAA CAA GTT GCT GCA ATG

OXR1 Isoforms 1&2

Forward

OXR1-E1-3-78bp REV

AGC ATT AAT ATC CAC CGA CTG G

OXR1 Isoforms 1&2

Reverse

OXR1-E1-3-78bp PRB

/56-FAM/TCT GTG TCT /ZEN/AAT CTA TCA TGG CTG AAG A/3IABkFQ/

OXR1 Isoforms 1&2

Probe

OXR1-E2-3-80bp FWD
OXR1-E2-3-80bp REV

CCT GCC TGC ACA GAA ATG A
GGA GCA TTA ATA TCC ACC GAC TG

OXR1 Isoforms 3
OXR1 Isoforms 3

Forward
Reverse

OXR1-E2-3-80bp PRB

/56-FAM/AAA CAG CCC /ZEN/AGG GCT GAA GAA A/3IABkFQ/

OXR1 Isoforms 3

Probe

OXR1-E18-87bp FWD

CAG AAG CAA CTC CCT CAT CTA C

OXR1 E18

Forward

OXR1-E18-87bp REV

CAG TAA ATG CTT CCT CCT CCT C

OXR1 E18

Reverse

OXR1-E18-87bp PRB

/56-FAM/TGG TAT TCG /ZEN/ACC TGC ACG AGT TGT /3IABkFQ/

OXR1 E18

Probe

RASSF4-E4-103bp FWD Set 1

GGC TCC TCA ACA TTG CCT

RASSF4 E4

Forward

RASSF4-E4-103bp REV Set 1

CGT CTG GGC ATC CAT GAG

RASSF4 E4

Reverse

RASSF4-E4-103bp PRB Set 1

/56-FAM/ATG CAG GAT /ZEN/GAC CGG GAG CA/3IABkFQ/

RASSF4 E4

Probe

Exon2 +3j FWD Set 1

GGA AGA GAA GAT GAA GGA AGA

RASSF4 Exclusion

Forward

Exon2+ 3j REV Set 1

CAT GGT AGC AGT TGT AGG T

RASSF4 Exclusion

Reverse

Exon2 +3j PRB Set 1

/56-FAM/CAG AAT CGG /ZEN/AGC TCT TAG GCC TGC TG/3IABkFQ/

RASSF4 Exclusion

Probe

Intron Inclusion FWD Set 1
Intron Inclusion REV Set 1
Intron Inclusion PRB Set 1

CCT AGG AGT ACA TGT GTG TCT TTC
CCT CGA TGA TCA GAG TCC CT
/56-FAM/ACA ACT GCT /ZEN/ACC ATG AGG GCA AGA /3IABkFQ/

RASSF4 Inclusion
RASSF4 Inclusion
RASSF4 Inclusion

Forward
Reverse
Probe
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Table 3: Custom primers designed for competitive PCR
Gene

Name

Sequence

Target

Direction

C20orf204

196421-E5 FWD
196421-E6 FWD
196421-E8 FWD
196421-E8a FWD
196421-E9 FWD
196421-E11 REV
196421-E12 REV
196421-E12a REV
196421-E13 REV

TCC TAC TGT ACC CCC AAG AGC CTG
GCG CCA TCA TCT TCG AGG ATC TGC AG
TCC TGT GGC GCC CAG AA
AAA ACC TGA CTA GAC CCG GGA GCT CGG
CGG CCT GCT CCT CTC TCA GTT T
ACC CAG CCC GAC TTC AGC CTA
TTT ATT GAG GCC TTC GGC GCG T
AAC AAG TCT ACA GAA CGA GGC GCG TCT
TAC GTG ACG TTT TAG GGG CCC CAG

C20orf204 E5
C20orf204 E6
C20orf204 E8
C20orf204 E8
C20orf204 E9
C20orf204 E11
C20orf204 E12
C20orf204 E12
C20orf204 E13

Forward
Forward
Forward
Forward
Forward
Reverse
Reverse
Reverse
Reverse

267053-E2-FWD

TGC GTC TGA GTC TGG GCT GAG A

CDLINC E1

Forward

267053-E2a-FWD

GAG GGT CCA GCA GCA GGA AGA AAC

CDLINC E1

Forward

267053-E2b-FWD
267053-E3-FWD

AAG AAA CCT CAG ACA GAT CGC CG
AGG GTC CAG CAG CAG GAA GAA AC

CDLINC E1
CDLINC E2

Forward
Forward

267053-E3a-FWD

AGA AAC CTC AGA CAG ATC GCC GG

CDLINC E2

Forward

267053-E3b-FWD

GAA ACC TCA GAC AGA TCG CCG G

CDLINC E2

Forward

267053-E8-REV

TCA GGT GAA GGT CAG CGC ACA CT

CDLINC E4

Reverse

267053-E8a-REV

CGA TGC TCT CGT GGT CAG CA

CDLINC E4

Reverse

267053-E10-REV

TGC ACA AAG AAA ACG CCC ATG TTG

CDLINC E5

Reverse

267053-E10a_REV

CCT TCT CTT CAA CAC CAC CCC ACC

CDLINC E5

Reverse

267053-E10b-REV

ACC CCA CCC TCC AGA AGT TTC C

CDLINC E5

Reverse

OXR1-E1 FWD

GAC TCC TCA ACA AGT TGC TGC

OXR1 E1

Forward

OXR1-E2 FWD

TGA CGA AGG ACA AAA ACA GCC CAG G

OXR1 E2

Forward

OXR1-E2a FWD

GCC TGC CTG CAC AGA AAT GAC GAA GG

OXR1 E2

Forward

OXR1-E2-3 FWD
OXR1-E18 REV
Exon 2j + Int (200)
FWD Set 1
Exon 2j + Int (200)
REV Set 1
Int + Exon 3j (200)
FWD Set 1
Int + Exon 3j (200)
REV Set 1

GGA CAA AAA CAG CCC AGG GCT GAA G
CTC GTG CAG GTC GAA TAC CAG TG

OXR1 E2
OXR1 E18

Forward
Reverse

TTC AGA AGT AAG CCT TGG TGT G

RASSF4 E2

Forward

CAG CCA TGG TCA TGT GTA GC

RASSF4 I2

Reverse

AGT CTG GTC TCC TCT GGT TAT

RASSF4 I2

Forward

GCT CTT GCC CTC ATG GTA G

RASSF4 E3

Reverse

CDLINC

OXR1

RASSF4

Differential Gene Expression by Oncogenotype
Initial analysis of the RNASeq data set was performed using Ballgown [131] for
differential gene expression based on the oncogenotype status of the KRAS or p53 gene shown
in table 4. From this analysis, RASSF4 (ENSG00000107551; figures 3-4) was selected for
differential gene expression validation. Expression of RASSF4 is shown in figure 3.
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Figure 1: Transcriptomics workflow
After culturing all cell lines were rested for 24 hours before harvesting in serum free RPMI to
equalize the growth factors received. Samples were then collected and underwent RNA
extraction before being sent out for subsequent library preparation and paired-end RNA
sequencing. The raw reads were obtained in fastq file format and aligned to the Hg38 version of
the human genome using the HISAT2/Stringtie [131] software suite. Finally transcriptomic
analysis via Ballgown [131] and spliceomics analysis using DEXSeq [134] was performed.

Table 4: Initial oncogenotype status of sequenced cell lines
Cell line

KRAS

TP53

HBEC

wt

wt

H1299

wt

null

H1792

G12C

null

A549

G12S

wt

H838

wt

wt

The genomic mutational status for the KRAS and TP53 gene loci is shown for each of the 5 cell
lines sent out for sequencing a of the time of sequencing. H1792 and A549 cell lines represented
those with mutations in KRAS expression. H1299 and H1792 cell lines represent those with
mutations in TP53.

Differential Exon Usage by Oncogenotype
DEXSeq [134] was used to identify differential exon usage by oncogenotype status
shown in Table X. Significantly differentially expressed exons shown in figure 2 were identified
as those with a padj of <0.01 and a fold change of +/- 5 in order to stringently identify potential
alternative splicing events.
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Figure 2: Number of genes with significantly differentially expressed exons by oncogenotype
Differential exon usage revealed significant differential expression in 289 genes in KRAS
oncogenotype alone, 62 genes in TP53 oncogenotype alone and 4 that both subgroups had in
common.

From these genes showing differentially expressed exons, 3 targets were selected for
further exon expression validation: OXR1 (ENSG00000164830; Figures 5-9) and CDLINC
(ENSG00000267053; Figures 12-14) from the p53 oncogenotype set and C20orf204
(ENSG00000196421; Figures 10-11) from the KRAS oncogenotype set.

RASSF4
RASSF4 (ENSG00000107551; figures 3-4) was identified through different gene
expression using Ballgown in R by separating the sequenced cell lines into groups based on their
p53 oncogenotype. This created 3 groups: control (HBEC), p53 mutant (H1299 and H1792) and
p53 wildtype (A549 and H838). Figure 3 shows the gene expression of these groups at the
transcript level based on genomic location. There are twelve transcripts shown for RASSF4. The
twelfth transcript shows an intron inclusion event between exon 2 and exon 3. This event is
unique to this transcript in RASSF4 and differentially occurs dependent on the oncogenotype
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grouping. This expression pattern was further validated by qRT-PCR amplification of either the
intron inclusion or intron exclusion event using primers shown in table 2 is shown in figure 4.

Figure 3: Differential gene expression of RASSF4 (ENSG00000107551)
Differential gene expression for RASSF4 (MSTRG.4231; ENSG00000107551) shown for
Control (HBEC; top left), TP53 mutant (H1299, H1792; top right) and TP53 wildtype (A549,
H838; bottom left). Expression levels are shown from low (white) to high (red). An intron

17

inclusion event is shown in the last transcript on each chart with high expression levels only in
those cell lines with mutant TP53 genes.

Figure 4: In vitro expression of differentailly expressed isoforms of RASSF4
Expression of an intron inclusion event identified by differential gene expression in Ballgown
was confirmed in vitro using ΔΔ CT method of qRT-PCR. Primers targeting the intron inclusion
event included a probe located on the junction of RASSF4 exon 2 to the intron. Primers targeting
the intron exclusion event included a probe located on the exon 2 to exon 3 juntion. Expression
levels are normalized to the HBEC (HBEC3KT) cell expression levels. Higher levels of the
intron inclusion event were seen in the HBEC, H1299 and H1792 cell lines.

OXR1
OXR1 (ENSG00000164830; Figures 5-9) was identified through differential exon usage
in R by DEXSeq. Significant differential usage of exons 1 and 3 can be seen in figure 5. Figure 5
also shows high levels of usage of the first exons for each of the top 3 transcripts. Figures 6 and
8 respectively show the design for the primers to amplify OXR1 by competitive PCR using
primers shown in table 3 or qRT-PCR using primers shown in table 2. Amplification patters
showed increased expression of all 3 isoforms in cell lines that were mutant at the TP53 locus as
seen in figures 7 and 9. This change in expression between the first two isoforms and the third
isoform was not significant enough to move forward with analysis on OXR1 past initial
validation.
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Figure 5: Differential exon usage for OXR1 (ENSG00000164830)
Graphical representation of differential exon usage expression levels determined by DEXSeq for
OXR1. Red represents the exon usage levels for samples that are mutant for the TP53 gene
(H1299, H1792) and blue represents exon usage levels for samples that are wildtype for TP53
(HBEC, A549 and H838). Exons 1 and 3 show increased usage specific to the TP53 mutant
oncogenotype. The first two transcripts contain both differentially utilized exons. The third
transcript contains only one of the differentially utilized exons. The third exon was identified as
significantly differentially expressed by the DEXSeq program as signified by the purple line
connecting its expression to its transcript location.

C20orf204
C20orf204 (ENSG00000196421; Figures 10-11) was identified through differential exon
usage in R by DEXSeq. C20orf204 showed significant differential expression of and exon
inclusion or exclusion based on KRAS oncogenotype status. While primers to ideally amplify
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and validate this expression via competitive PCR were created for the locations shown in figure
12, amplification of this gene in vitro was not successful.

Figure 6: Primer design for qRT-PCR in vitro validation of differential exon usage in OXR1
(ENSG00000164830)
Primers for qRT-PCR validation of OXR1 were designed using the DEXSeq differential exon
usage graphical representation output. Red represents the exon usage levels for samples that are
mutant for the TP53 gene (H1299 and H1792) and blue represents exon usage levels for samples
that are wildtype for TP53 (HBEC, A549 and H838). The red box highlights exon 3 which is
differentially expressed. The first two transcripts have nearly every exon in common and it was
decided they would be targeted together by primer set OXR1-E1-3-78bp containing a forward
primer in exon 1, reverse primer in exon 3 and probe covering the exon 1-exon 3 junction shown
by the blue arrows. The third transcript was targeted by primer set OXR1-E2-3-80bp containing
a forward primer in exon 2, reverse primer in exon 3 and a probe covering the exon 2-exon 3
junction shown by the red arrow.
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Figure 7: In vitro expression of differentially expressed isoforms of OXR1 (ENSG00000164830)
Expression levels for OXR1 measured using ΔΔ CT method of qRT-PCR. Isoforms 1&2 were
amplified using primer set OXR1-E1-3-78bp containing a forward primer in exon 1, reverse
primer in exon 3 and probe covering the exon 1-exon 3 junction. Isoform 3 was targeted by
primer set OXR1-E2-3-80bp containing a forward primer in exon 2, reverse primer in exon 3 and
a probe covering the exon 2-exon 3 junction. Higher levels of all isoforms measured were seen in
HBEC (HBEC3KT), H1299 and H1792 samples. Increased expression was expected in those
samples mutant for TP53 and very low levels of expression in was seen in A549 and H838.

CDLINC
CDLINC (ENSG00000267053; Figures 12-14) was identified through differential exon
usage in R by DEXSeq. Significant differential usage of exon 8 can be seen in figure 5. Figure 5
also shows high levels of usage of the first exons for each of the top 3 transcripts, the major
isoforms of CDLINC: A, B and C. Figure 13 shows the design used to amplify isoform specific
regions via qRT-PCR to identify the expression levels of CDLINC A, B and C in vitro.
Initially, CDLINC was suspected to show differential expression and exon usage based
on those samples sequenced containing either wildtype (wt) or mutant (P53) genomic sequences
for TP53. After amplification in vitro, this pattern did not hold up, but a significant difference in
the expression of the A versus the B and C isoforms was evident as seen in figure 14. A549 and
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Figure 8: Primer design for competitive PCR in vitro validation of differential exon usage of
OXR1 (ENSG00000164830)
Primers were designed to target the first two transcripts for in vitro validation by amplifying the
region from E1 forward to E18 reverse. Forward primers designed to target exon 1 (E1) or exon
2 (E2) were paired with a reverse primer targeting exon 18 in order to differentiate between the
first two transcripts which contain the mutually exclusive exon 1 or the third transcript
containing the mutually exclusive exon 2.

H838 cell lines showed no detectable levels of CDLINC B or C expression while H1299
and H1792 cell lines showed high levels of expression of CDLINC B and C. All cell lines tested
showed expression of CDLINC A.

Discussion
As this research was underway it became clear that the H838 cells were following the
same pattern as those with p53 mutations. The H838 mutation status was originally believed to
be wildtype for both p53 and KRAS, which was why it was chosen for sequencing and this
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study. Upon further review, the literature was divided on whether it is a p53 mutant. ATCC has
H838 listed as a p53 truncation mutant and we confirmed this via Western blotting (Appendix
B). This altered our analysis from the initial findings and the findings from Appendix B were
used to continue analysis of CDLINC in Chapter Three.

Figure 9: In vitro expression of isoforms 1&2 of OXR1 (ENSG00000164830)
After PCR amplification samples were run on an agarose gel containing ethidium bromide then
imaged by ultraviolet fluorescence. The expression patterns showed amplification patterns
consistent with the expected results from in silico analysis. Expression of the first exon (E1) was
predicted to be identifiable only in cell lines with mutations in TP53 based on the DEXSeq
results. Primers for E2 forward to E18 reverse were unsuccessful in producing an amplified
product. Primers specific to OXR1 (ENSG00000164830) were designed to verify the presence
and/or absence of transcripts utilizing forward primers targeting in exon 1 and reverse primers
targeting exon 18 in vitro to confirm in silico findings.
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Figure 10: Differential exon usage for C20orf204 (ENSG00000196421)
Graphical representation of differential exon usage expression levels determined by
DEXSeq for C20orf204. Red represents the exon usage levels for samples that are mutant for the
KRAS gene (A549 and H838) and blue represents exon usage levels for samples that are
wildtype for KRAS (HBEC, H1299 and H1792). Exon 10 was identified as having significant
differential exon usage as shown by the purple designation. Samples which are Mutant for
KRAS show decreased usage of exon 10. Exon 10 is present in 3 of the 5 isoforms.

RASSF4 has an upregulated intron exclusion event in cells which are mutant for p53 as
shown in figures 3 and 4. Although we were able to confirm the bioinformatic findings, the
overall upregulation of the event was low compared to the overall gene expression of RASSF4
and in light of the change in H838 status, we decided not to continue analysis with RASSF4 .
OXR1 differential exon usage seen in figure 5 was confirmed by both qRT-PCR (figures 6 and
7) and competitive PCR (figures 8 and 9). OXR1 showed the same expression patterns we
witnessed from the differential exon usage analysis (figures 7 and 9) with increased expression
of isoforms 1 and 2 in those cell lines that have mutant p53 genes. With the change in p53
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classification of H838, these findings are no longer tied directly to the oncogenotype and we
decided not to continue analysis with OXR1. C20orf204 proved difficult to amplify from in vitro
samples in the lab (figures 10 and 11). For this reason, we chose not to continue analysis with
C20orf204.

.

Figure 11: Primer design for competitive PCR in vitro validation of differential exon usage of
C20orf204 (ENSG00000196421)
C20orf204 has 5 transcripts. Two of the transcripts encode for protein and three result in
retained introns which do not undergo translation. Primers were designed to target all locations
identified by red arrows. The red oval and box both indicate the significant different exon usage
of exon 10. Initial amplification results were ineffective, and this target was not selected for
further analysis
Another determination which altered our initial in vitro findings was in using HBEC3kT
instead of the harder to culture HBEC primary cells for amplification using primers designed to
validate the in-silico findings. HBEC3KT cells are an immortalized cell line derived from HBEC
primary cells. Their immortalization is achieved through the overexpression of Cdk4. After
initially using HBEC3KT cells as a lab available control cell line, the concern was raised that
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that, since HBEC3KTs overexpress CDK4, this may mimic the p53 oncogenotype due to the
normal inhibition of Cdk4 through p21 activation by p53. Therefore, HBEC3KT was removed as
the control cell line from the qRT-PCR validation for further studies.

Figure 12: Differential exon usage for CDLINC (ENSG00000267053)
Graphical representation of the initial differential exon usage expression for CDLINC showed
significant differential usage of exon 8 with those cell lines with mutant TP53 (H1299 and
H1792; red) showing much higher expression levels than those with wildtype (wt) TP53 (HBEC,
A549 and H838; blue). The exon usage of the first three transcripts (A, B and C) are responsible
for much of the increase seen.

From this initial study ENSG00000267053, which we later renamed CDLINC, was
selected to move to biological validation via “knockdown”, overexpression, biological assays
and further bioinformatic analysis due to the large fold change difference and clear expression
pattern difference. The OXR1 and RASSF4 were also validated but did not show as strong of an
alternative splicing effect and due to time constraints only one target was selected for biological
assays.
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Figure 13: Primer design for qRT-PCR in vitro validation of differential exon usage in CDLINC
(ENSG00000267053)
Primers were designed to target the first three transcripts of CDLINC to identify which
transcript(s) is responsible for the differential usage of exon 8 shown in the red box and oval,
which is present in all isoforms. Primer set 267053-E2-5-109bp in blue targets isoform A with a
forward primer in exon 2, a reverse primer in exon 5 and a probe covering the exon 2-exon 5
junction. Primer set 267053-E2-8-147bp in purple targets isoform B with a forward primer in
exon 2, a reverse primer in exon 8 and a probe covering the exon 2-exon 8 junction. Primer set
267053-E3-8-127bp in green targets isoform C with a forward primer in exon 3, a reverse primer
in exon 8 and a probe covering the exon 3-exon 8 junction.

Figure 14: Expression of CDLINC (ENSG00000267053) is high in CDKN2A-mutant cell lines.
Expression for the three main isoforms of the CDLINC gene are shown after normalization to β
Actin gene expression and HBEC (HBEC3KT) expression levels using the ΔΔCT method.
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CHAPTER THREE: CDKN2A DEPENDENT LONG INTERGENIC NON-CODING
RNA (CDLINC)

Abstract
Long intergenic non-coding RNAs (lincRNAs) share many features with protein coding
mRNAs such as capping, splicing, and polyadenylation. Alternative splicing of these lincRNAs
may play a role in cancer progression and provide novel targets for new therapeutic development
[54]. Similar to many cancer-testis antigens, the previously uncharacterized lincRNA CDLINC,
encoded on chromosome 19, maintains high endogenous expression only in the testes. We here
report that CDLINC amplification in TGCA studies is strongly correlated with decreased
survival and decreased disease-free progression. NSCLC and TNBC cells normally express the
nuclear CDLINCa, but only those which are CDKN2A positive express the cytoplasmic
CDLINCb and CDLINCc isoforms. Specific reduction of the cytoplasmic isoforms decreases
proliferation and colony formation in CDKN2A wildtype NSCLC cell lines. Conversely,
overexpression of the cytoplasmic isoforms increases proliferation and colony formation ability
in NSCLC cell lines. These findings suggest a novel CDKN2A-mutational status dependent role
for CDLINC in the progression of NSCLC.

Introduction
Every day over 400 Americans will die of lung cancer [6, 7]. Lung cancer will account
for about 23% of all US cancer deaths, or an estimated 135,720 deaths in 2020. Worldwide it
will be responsible for more than 1.6 million deaths [5]. Although some targeted therapeutics do
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exist, in most cases current drug therapies struggle to treat this common and high mortality
cancer due to the heterogeneous genomic and transcriptomic profiles of this disease [18-34].
Very few patients with NSCLC are eligible for screening for personalized therapeutics. Hence, in
most cases, the molecular drivers of the tumor remain unknown [35]. Personalized targeted
therapeutics based on molecular markers is a quickly progressing field in lung cancer research,
yet many lung cancers are still lacking effective treatment options [34, 36-45].
Non-coding RNAs (ncRNAs) are emerging as critical regulators in cancer tumorigenesis
and cancer progression [54]. NcRNAs are broken into two subcategories based on their size.
Those greater than 200 nucleotides (nt) in length are long non-coding RNAs (lncRNAs), which
include long intergenic non-coding RNAs (lincRNAs), and those less than 200 nt are short noncoding RNAs, such as micro RNAs (miRNAs) which are typically around 21-24 nt.
LncRNAs are typically transcribed by RNA polymerase II and have 5’ methyl caps as
well as 3’ poly(A) tails. Broad mechanisms of regulating gene expression by lncRNAs include
acting as miRNA sponges, decoys or guides for transcription factors, forming nuclear structures
or R-loops, mediating inter-chromosomal interactions, regulating post-transcriptional mRNA
decay, regulating cellular localization of RNA- or DNA- binding proteins and other yet to be
discovered modes. One mechanism of lncRNA function is as miRNA sponges, allowing them to
function as competing endogenous RNAs (ceRNAs) [135] and play key roles in cancer disease
states [64].
A subset of lncRNAs in cancer are known as the Cancer/Testis Antigens (CTAs) [127,
128]. CTAs are lncRNAs that are endogenously highly expressed only in the testes and tend to
also be highly expressed in cancer suggesting an oncogenic role for them. These CTAs play roles
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in cell cycle progression necessary for spermatogenesis, a function that is then highjacked by
cancer to promote its own progression.
Through transcriptomics we have identified a novel alternatively spliced uncharacterized
CTA lincRNA located on the plus strand of chromosome 19, which we have renamed CDKN2A
Dependent Long Intergenic Non-Coding (CDLINC). CDLINC has 10 annotated alternatively
spliced transcripts with 3 main isoforms: CDLINCa, CDLINCb, and CDLINCc. CDLINCa, the
“basal” isoform, is expressed in all cell types/lines tested, but the other two isoforms (CDLINCb
and CDLINCc) were only found to be expressed in CDKN2A-positive cell lines. Downstream of
CDLINC on the minus strand of chromosome 19 is another novel lincRNA consisting of 10
known alternatively spliced transcripts that share sequence similarity to the main isoforms of
CDLINC. We have named this alternate lincRNA Alt-CDLINC.

Materials and Methods
Bioinformatic Analysis
Raw read files from sequencing were first checked for quality using FASTQC [130] then
aligned using HISAT2 and assembled using Stringtie as described previously according to the
sample default instructions [131] to Hg38 (GENCODE 27 and Ensembl 91 [132, 133]).
Differential exon usage was analyzed using DEXSeq [134] as described by the program
publisher to identify exons with significant differential exon expression as defined as an adjusted
p-value of less than or equal to 0.05. DEXSeq uses a binomial distribution followed by
generalized linear models and a Benjamini-Hochberg p-value adjustment to obtain the final pvalue. Biostatistics analysis utilized either R, GraphPad Prism 5 or Kaplan-Meier survival and
disease-free progression. Tests included t-test (between two samples) and ANOVA with Tukey
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post-test for more than 2 samples. The Cancer Genome Atlas (TCGA) data was accessed via the
Genomic Data Commons (GDC) portal [136] and cBioPortal [137, 138] to analyze the overall
survival and disease free progression of samples from The Cancer Genome Atlas Pan Cancer
Atlas 2018.

Reagents and Antibodies
Custom expression plasmid constructs for CDLINCa (ENST00000586345.6), CDLINCb
(ENST00000586488.6) and CDLINCc (ENST00000590845.1) were created to our specifications
using GeneArt Gene Synthesis (Invitrogen) and subsequently cloned into pcDNA3.1(+) vector
for overexpression assays.

Custom Primers, RNAi and ASOs
Custom primers were designed using Integrated DNA Technologies (IDT) custom DNA
oligos and custom probes tools. Custom RNAis were designed using Horizon Discovery Custom
siRNA Synthesis design tool. Custom ASOs were designed using IDT Antisense Oligonucleotide
guidelines and synthesized by IDT. All custom primers, RNAi and ASOs are listed in tables 3-4
(primers) and A3 (RNAi) as well as appendix D (ASOs).

Cancer Cell Lines and Media
The NSCLC cell lines A459, H358, H838, H1299, H1792 and H1869, human bronchial
epithelial primary cells (HBEpC) and TNBC cell lines MDA-231 and MDA-468 (purchased
from American Type Culture Collection, ATCC) were cultured in RPMI (Gibco) with the
exceptions of A549 and H1869 (DMEM, Gibco) and HBEpC (Airway Epithelial Cell Basal
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Medium and Bronchial Epithelial Cell Growth Kit, ATCC). All DMEM and RPMI was
supplemented with 10% fetal bovine serum (FBS, Gibco) and 1% penicillin/streptomycin
(Gibco). Cell lines were maintained in a 37°C incubator with 95% air and 5% CO2. Cells were
maintained at less than 90% confluency. Experiments were performed within the first 15
passages for all cell lines except HBEpC which was limited to 5 passages.

RNA Isolation and Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR)
Total RNA was isolated by manufacturer’s protocol using either the RNeasy Mini Kit
(Qiagen) or Quick-RNA Miniprep (Zymo Research) as described previously [139-141] and
purified when necessary by RNA Clean & Concentrator (Zymo Research) following
manufacturer’s protocol. RT-PCR was performed as described previously [46, 129] using High
Capacity cDNA Reverse Transcription Kit (Applied Biosystems) and RNase Out (Invitrogen).
RNA and cDNA were stored at –80°C.

Quantitative Real time Polymerase Chain Reaction (qRT-PCR)
Custom and premade primers listed in table 2 were used for qRT-PCR as described
previously [46]. Relative mRNA expression was normalized to either β Actin or internal levels
(primer “ALL”) using the ΔCT or ΔΔCT method.

Protein Extraction and Western Blotting
Pelleted cells for protein extraction were processed as previously described [46, 139142]. Briefly, samples were resuspended in CelLytic (Sigma-Aldrich) with 1%
protease/phosphatase inhibitor and sonicated on ice for 5 seconds prior to quantification.
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Laemmli buffer (Bio-Rad) containing 5% beta mercaptoethanol was then added and the samples
were boiled at 95°C for 5 minutes before Western blotting. Western blotting was performed as
previously described [46, 129, 142, 143] using 30-60 μg of protein per sample.

Nuclear Extraction
Nuclear extraction was performed as described in the Thermo Fisher Scientific protocol
modified for RNA by using RNase-free lysis buffer for RNA extraction to resuspend the nuclear
fractions. Prior to RNA extraction, 10% of each sample was transferred to a separate tube for
protein extraction. Both nuclear and cytoplasmic RNA samples then underwent RNA isolation as
described above using the Qiagen RNA extraction kit.

RNAi Transfection
A549, H358, H838, H1299, or H1792 cells were seeded at 50% confluency in 6-well
plates the day before transfection with RNAi (non-targeting control or B+C), plasmid (GFP
control, CDLINCa, CDLINCb, CDLINCc or combination of CDLINCb & CDLINCc), or ASO
(antisense control, nuclear localizing motif or CDLINCa) as described previously [46, 139-141,
143] with sequences shown in Table A3. Briefly, for RNAi cells were transfected using
Dharmafect 2 (Horizon Discovery) and a working concentration of 100 nM siRNA in complete
media.

Plasmid Transfection
For overexpression plasmids, cells were transfected using Lipofectamine 3000
(Invitrogen) and a working concentration of 0.5 μg/mL plasmid in OptiMEM (Gibco) and the
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media was replaced with complete media 4 hours after transfection. For ASOs, cells were using
Lipofectamine 3000 (Invitrogen) and a working concentration of 100 nM ASOs.
24-48 hours post-transfection, cells were seeded for proliferation, clonogenics and soft
agar biological assays as described previously and below [141, 144].

Proliferation Assay
Cells were plated onto 96-well plates at 5x103 cells per well as previously described [129,
139, 145] and the media was changed every 3 days. WST-1 assay (Sigma-Aldrich) was
performed according to manufacturer’s instructions. WST-1 dye was added and 440nm
absorbance was measured on a BioTek Synergy 2 plate reader on alternating days 0-6.

Clonogenics Assay
Clonogenic assays were performed as described previously [141, 145] with the following
modifications: 250 cells per well were used, cells were fixed with 10% formalin and fixation was
performed 10-14 days after seeding the assay.

Soft Agar Assay
Anchorage independent colony formation soft agar assays were performed as described
previously [144]. Briefly, 1x104 cells were seeded in 0.35% agarose media over solidified 0.5%
agarose media. 1 mL of media was replaced every 3 days to keep the assay moist and sustain
colony formation. After 3-4 weeks 0.05% iodonitrotetrazolium chloride (Sigma-Aldrich) was
added to stain the cells and the number of colonies present in each well were counted.
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Results
Transcriptomic Identification
The genomic location and all known aliases were identified for CDLINC (table 5) and
Alt-CDLINC (table 6). NCBI BLAST alignment results of CDLINC to Alt-CDLINC isoforms is
shown in table 7. Alt-CDLINC is located about 1 million base pairs downstream of CDLINC on
the minus strand of chromosome 19. Alt-CDLINC is the only other location in the human
genome with the exact same sequence contained in the 170-nucleotide long exon 4 of CDLINC.
There is no known conservation of CDLINC or Alt-CDLINC between species and only partial
conservation with the higher apes. No conservation is found in mice and limited conservation
found with few primates. All isoforms for CDLINC and Alt-CDLINC are shown in figure 15.
Both lincRNAs have 3 major isoforms: A, B and C with at least one version of each.

Table 5: Genomic location and aliases for CDLINC
Chromosome 19: 36,304,564-36,321,274 (+)
Source
This Paper
Ensembl
Ensembl
NCBI Entrez
NCBI Gene ID
LNCipedia
NONCODE
LncBook
Havana ID

Alias
CDLINC (+)
ENSG00000267053.8
AC092296.2
LOC100134317
CTD-3162L10.1
LNC-ZNF146
NONHSAG025648.2
HSALNG0125744
OTTHUMG00000180576.1

Genomically, these two lincRNAs are very difference, however, transcriptomically they
contain nearly identical RNA sequences as evident in table 7. Every transcript of both genes
carries a 100% identical 170 nucleotide exon 4. Furthermore, all A, B and C transcripts of
CDLINC and Alt-CDLINC carry an identical 130 nucleotides found in exons 1 and 2. This 130-
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nucleotide sequence is found in full or at least partially 66 times in the human genome over 4
chromosomes. Several loci containing these sequences are predicted to be rRNA pseudogenes.

Table 6: Genomic location and aliases for Alt-CDLINC
Chromosome 19: 37,235,507-37,304,395 (-)
Source
This Paper
Ensembl
Ensembl
NCBI Entrez
NCBI Gene ID
LNCipedia
NONCODE
LncBook
Havana ID

Alias
Alt-CDLINC (-)
ENSG00000267605.7
AC016590.1
LOC284412
CTD-3220F14.1
LNC-ZNF585B-5
NONHSAG025684.2
HSALNG0125832
OTTHUMG00000180577.1

Our analysis demonstrates that exons 1 and 2 are non-unique non-coding RNA
sequences, whereas exon 4 is unique to the CDLINC/Alt-CDLINC loci. Due to this, exon 4 was
chosen as a CDLINC/Alt-CDLINC target for RNAi interference in this study. Supplementary
figures are in Appendix D.

Table 7: Alignment results for CDLINC to Alt-CDLINC
CDLINC (nt)

Isoform

Alt-CDLINC (nt)

Query Coverage

Identities

Match

AC092296.2-201 (952)

A

AC016590.1-201 (1208)

95%

876/909

96.37%

AC016590.1-205 (813)

100%

809/813

99.51%

AC016590.1-206 (924)

100%

891/924

96.43%

AC092296.2-202 (566)

B

AC016590.1-204 (547)

100%

543/547

99.27%

AC092296.2-204 (439)

C

AC016590.1-202 (420)

93%

410/412

99.51%
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Figure 15: Schematic of CDLINC and Alt-CDLINC Isoforms
Schematic of all 10 CDLINC and 10 Alt-CDLINC transcripts from Ensembl v99 in numerical
transcript order (201-210). Exons 1 and 2 share a 130 nt sequence which is present 66 times (at
least partially) in the human genome making the junction from exons 1-4 found in the B isoforms
and exons 2-4 found in the C isoforms identical. Exon 4 is 170 nt and is the only exon shared by
all 10 transcripts of both CDLINC and Alt-CDLINC making it the ideal location for CDLINC
specific targeting. Red indicates the A isoform containing at least exons 1, 3, 4 and 5. Blue
indicates the B isoform containing at least exons 1, 4 and 5. Purple indicates the C isoform
containing at least exons 2, 4 and 5. Grey indicates secondary isoforms which do not undergo the
same level of alternative splicing.

Endogenous Expression
Endogenous expression of CDLINC and Alt-CDLINC are shown in figures 16-17 from
GTEx Portal. Both lincRNAs are endogenously highly expressed in the testis and somewhat in
the cerebellar brain as well. The lungs do not have high levels of endogenous expression of
either CDLINC or Alt-CDLINC. These endogenous expression patterns showed extremely low
levels of these genes in normal lung tissue expression for all isoforms, indicating that increased
expression of these RNA species is dysregulated in some lung cancers.
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Figure 16: Expression of endogenous CDLINC and Alt-CDLINC is testis-specific
GTEx Portal CDLINC (A) and Alt-CDLINC (B) GENCODE 26 endogenous gene expression in normal tissue measured in transcripts
per million reads (TPM) across many tissue types. Arrows indicate lung tissue which has low endogenous expression levels. Notable
is the high level of endogenous expression in the testis.
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Figure 177: Endogenous CDLINC and Alt-CDLINC isoform expression is testis-specific
CDLINC (A) and Alt-CDLINC (B) GENCODE 26 isoform expression quantification expression in normal tissue across many tissue
types. Arrows indicate lung tissue which has low endogenous expression levels. Notable is the high level of endogenous expression in
the testis.
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Figure 18: CBioPortal CDLINC genomic alteration frequency
Gene level alteration data showing genomic amplifications (red) and genomic deep deletions (blue) across all cancer types from the
TCGA PanCancer Atlas 2018 for all samples that also contained mutation and CNA data (n=9892). Arrows mark Non-Small Cell
Lung Cancer (NSCLC) with a 3-4% genomic alteration rate of primarily genomic amplification.

40

Figure 19: CBioPortal Alt-CDLINC genomic alteration frequency
Gene level alteration data showing genomic amplifications (red) and genomic deep deletions (blue) across all cancer types from the
TCGA PanCancer Atlas 2018 for all samples that also contained mutation and CNA data (n=9892). Arrows mark Non-Small Cell
Lung Cancer (NSCLC) with a 3-4% genomic alteration rate of primarily genomic amplification.
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A)

B)

C)

D)

Figure 20: Altered expression of CDLINC and Alt-CDLINC in cancer is associated with
decreased overall and disease/progression free survival
Overall survival (A-B) and disease-free progression (C-D) from TCGA PanCancer Atlas 2018
for all cancer types. The genomic alterations seen in figures 18-19 correspond with the decreases
in overall survival and disease/progression free survival.
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Figure 21: Differential exon usage and localization of CDLINC
DEXSeq differential exon usage of CDLINC in NSCLC cell lines based on CDKN2A genomic status: Control (Ctr; HBEC), Mutant
(Mut; A549 and H838) and Wildtype (Wt; H1299 and H1792). Exon usage is normalized to overall gene expression levels. Counts are
normalized to size factors.
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Figure 22: Differential exon usage and localization of Alt-CDLINC
DEXSeq differential exon usage of CDLINC in NSCLC cell lines based on CDKN2A genomic status: Control (Ctr; HBEC), Mutant
(Mut; A549 and H838) and Wildtype (Wt; H1299 and H1792). Exon usage is normalized to overall gene expression levels. Counts are
normalized to size factors.
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B)

A)

C)

D)

Figure 23: CDLINC in vitro expression and localization
A) CDLINC expression for NSCLC and TNBC cell lines measured by qRT-PCR and normalized
to β-Actin expression. B) CDKN2A gene status and corresponding CDLINC isoform presence.
C) QRT-PCR expression of nuclear localization results for CDLINC normalized to common
exon 4 expression. E) Western Blot demonstrating separation of nuclear (N1-4) vs cytoplasmic
(C1-4) samples.
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Figure 24: RNAi downregulation of cytoplasmic CDLINC isoforms
QRT-PCR validation of CDLINC “knockdown” normalized to β-Actin expression in.NSCLC
cell lines treated with 100 nM of either siNT (CTR) or siCDLINC (targets exon 4; only effects
cytoplasmic isoforms; Cyto-KD)
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Figure 25: Downregulation of cytoplasmic CDLINC B+C effects proliferation
Proliferation as measured by WST-1 assay at 440nm after CDLINC B+C “knockdown”
treatment normalized to Day 0 reading in four NSCLC cell lines: A549, H1299, H1792 and
H358. All those cell lines except A549 endogenously express the cytoplasmic CDLINC B+C
isoforms. H1299 cells became too confluent to measure after day 2.
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B)

A)

Figure 26: Downregulation of cytoplasmic CDLINC B+C effects cancer phenotype
A) Clonogenic assay after treatment normalized to CTR colony counts. B) Soft agar assay after
treatment normalized to CTR colony counts. Results shown in two NSCLC cell lines: A549 and
H1299. A549 does not endogenously express the cytoplasmic CDLINC B+C isoforms and
H1299 does. Photos of the soft agar growth plates are in Appendix D.
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Figure 27: Downregulation of cytoplasmic CDLINC B+C effects CDKN2A-linked pathways and
cancer progression phenotypes.
Western blot showing effects of Cyto-KD downregulation of CDLINC on expression of key
proteins in the CDKN2A pathway.

TCGA Genomic Alterations and Prognosis
CBioPortal results for all TCGA 2018 Pan Cancer Atlas samples for all cancer types with
both copy number variation and gene expression data available and sorted by cancer type are
shown for CDLINC and Alt-CDLINC in figures 18-19 along with the available corresponding
Kaplan-Meier survival and disease/progression free survival data (Figure 20). Genomic
alterations occurred in both genes at roughly a 4% rate in NSCLC. These genomic alterations
were primarily amplifications of the genomic region with only a few deep deletions. Genomic
alterations in either gene are associated with significant decreases in overall survival and reduced
disease-free progression.
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In Vitro Expression and Nuclear Localization
CDLINC (and Alt-CDLINC) differential expression (Figures 21-23) shows a strong
correlation with the genomic status of CDKN2A. Cell lines/types which are CDKN2A-positive
express all 3 major isoforms, while those that have mutant/non-functional CDKN2A genes
express only the “basal” CDLINCa isoform. A nuclear localization analysis revealed that the
CDLINCa isoform is primarily located in the nucleus while the CDLINCb & CDLINCc isoforms
are primarily located in the cytoplasm (Figure 23).

Biological Assays
RNA interference experiments targeting the common exon, exon 4, revealed that
inhibiting the expression of the cytoplasmic isoforms of CDLINC reduced the cancer cell line’s
ability to proliferate, form clonogenic colonies and form colonies in an anchorage independent
fashion within soft agar (Figures 25-26). This “knockdown” of the cytoplasmic isoforms caused
significant increase in both p14ARF and p16INK4A (CDKN2A) protein expression as well as a
significant reduction in the phosphorylation of RB. The opposite effect on proliferation and
colony formation was observed when both cytoplasmic isoforms were overexpressed by plasmid
transfection into cancer cell lines (Figures 28-29).

Discussion
This study identified a novel connection between two novel lincRNAs, CDLINC and AltCDLINC, as shown in tables 5-7 and figure 15. These two lincRNAs share a unique 170
nucleotide sequence which is present in all ten isoforms of each gene. Their major isoforms A, B
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and C, while genomically different, are transcriptomically nearly identical making the expressed
ncRNAs from these two lincRNA genes essentially identical for the purposes of this study.

Figure 28: Plasmid driven upregulation of CDLINC
CDLINCa, CDLINCb, CDLINCc or GFP (control) were overexpressed in A549 and H1299
NSCLC cells via plasmid transfection. A549 does not endogenously express the cytoplasmic
CDLINC B+C isoforms and H1299 does. QRT-PCR was used to validate CLDINC
overexpression and was normalized to β-Actin expression.
51

A)

B)

Figure 29: Upregulation of cytoplasmic CDLINC B+C effects cancer progression phenotypes
CDLINCa, CDLINCb, CDLINCc or GFP (control) were overexpressed in A549 and H1299
NSCLC cells via plasmid transfection (figure 28). A549 does not endogenously express the
cytoplasmic CDLINC B+C isoforms and H1299 does. Twenty-four – 48 h later, A) Proliferation
(normalized to Day 0 reading) and B) clonogenic capacity (normalized to GFP clonogenic
capacity levels) were measured via WST-1 assay at 440 nm (A) or colony formation assay (B).
Significant increases in these indicators of a cancer phenotype occurred only when both
CDLINCb and CDLINCc were overexpressed together.
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Figure 30: Proposed mechanism of CDLINC function
Diagram showing CDLINC’s proposed function as oncogenic miRNA sponge for cytoplasmic
isoforms CDLINCb and CDLINCc. We propose that target tumor suppressing protooncogene
mRNAs are no longer downregulated when CDLINCb and CDLINCc act as a miRNA sponge.
These protooncogenes would then be able to downregulate the expression of the CDKN2A gene.

Table 8: MiRNAs predicted to bind to CDLINC
miRNA Name
hsa-miR-493-3p
hsa-miR-3180-5p
hsa-miR-4453
hsa-miR-2467-3p
hsa-miR-6868-3p
hsa-miR-205-5p
hsa-miR-3678-3p
hsa-miR-100-3p
hsa-miR-6515-3p
hsa-miR-676-5p
hsa-miR-125a-3p

Score
1
0.987
0.979
0.977
0.961
0.957
0.948
0.947
0.941
0.939
0.927

Table 8 shows the miRNAs with a score of 0.9 or greater predicted to bind to exon 4 of CDLINC
from lncbase predicted v2 (DIANA Tools, [146]).
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Table 9: IPA pathways predicted to be targeted by miRNAs from table 8
IPA Predicted Pathway
Synaptogenesis Signaling Pathway
Tight Junction Signaling
Molecular Mechanisms of Cancer

p-value
7.60E-11
5.74E-05
1.23E-04

Table 9 shows the top 3 IPA pathways affected by genes predicted to be targeted by miRNAs
from table 8 via miRDB [147] with score > or = 80.

B)

Figure 31: Effect of an Akt inhibitor on the expression of CDLINC
A) CDLINC expression as measured by qPCR normalized to β-Actin expression after treatment
with 100 nM BEZ235 (MTOR/PI3K inhibitor) and B) Western Blot of BEZ235 (Akt inhibitor)
treatment.
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CDLINC B and C contain a 130-nucleotide sequence which is found at least in partiality
66 times in the human genome. This similarity in their first exons mean that CDLINC B and C
are unable to be differentially identified by their ncRNA expression. Not only do these lincRNA
gene show such similarity in the expressed RNAs, but as shown in figures 16-17 their patterns of
endogenous tissue expression are nearly identical with high levels of expression in the testis and
otherwise low endogenous tissue expression in a manner similar to that expected from cancertestis antigens.
Our in vitro expression levels of CDLINC (and Alt-CDLINC) show that only cancer cell
lines with genomically functional CDKN2A genes (H358, H1299 and H1792 in lung cancer and
MDA468 in breast cancer) express CDLINC B and C isoforms as shown in figure 23. We also
have discovered that not only are CDLINC B and C differentially expressed, but their expression
is specific to their cellular location shown in figure 23. CDLINC A contains a nuclear
localization motif previously reported to be involved in the nuclear localization of long noncoding RNAs. This finding suggests that CDLINC A may have a different cellular function due
to its nuclear localization than CDLINC B and C. Our findings demonstrating differential
expression of CDLINC A versus B and C after treatment with an MTOR inhibitor provides
further evidence for this hypothesis.
When the expression of CDLINC B and C is downregulated via RNAi, the ability of the
NSCLC cells to proliferate, form colonies from a single cell and grow three-dimensionally
decreases as seen in figures 25-26. The opposite effect can be recapitulated when CDLINC B
and C are introduced to cancer cell lines which do not endogenously express CDLINC B and C
or when upregulated in cancer cell lines which express CDLINC B and C endogenously as seen
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in figures 28-29 where CDLINC B+C plasmid overexpression induce an increase in proliferation
and colony formation ability.
Our findings suggest a novel CDKN2A-linked role for the alternatively spliced
cytoplasmic isoforms of CDLINC and Alt-CDLINC in NSCLC progression. Specifically, the
cytoplasmic CDLINCb and CDLINCc isoforms play a role in increased cell proliferation
and colony formation ability. CDLINC is a lincRNA endogenously highly expressed in the testis
yet dysregulated in CDKN2A-positive cancer cells. CDLINC was identified as a novel CTA due
to its endogenous expression pattern and dysregulation in cancer. Like other CTAs, CDLINC
promotes cancer progression through increased proliferation and colony forming ability of its
cytoplasmic isoforms.

Proposed Mechanism
CDLINC is predicted to bind to many miRNAs on its common exon. We propose a
mechanism for dysregulation of the miRNAs due to CDLINC acting as a ceRNA in figure 30.
Ingenuity Pathway Analysis (IPA, Qiagen) top 3 predicted pathways dysregulated by these
miRNAs are shown in Table 6 and Figures 23-26 in Appendix D. Pathways that may be
dysregulated by CDLINC are shown in Figures 19 & 20. This dysregulation is highlighted by the
effect of BEZ235, an MTOR and PI3K inhibitor on CDLINC (Figure 31) and IPA analysis
results displaying the relationship between the predicted endogenous genes normally targeted by
the top predicted miRNAs and CDKN2A (Figure 32).
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Figure 32: CDLINC is predicted to bind to multiple miRNAs which regulate CDKN2A-linked
negative transcriptional regulators.
Biological molecules predicted to be targeted by miRNAs from table 8 in relation to the
CDKN2A pathway. Direct relationships are represented by solid lines; indirect relationships are
represented by dashed lines. Biological molecules include enzymes, kinases, ligand-dependent
nuclear receptors, transcriptional regulators and other. Experimentally validated gene targets are
designated with an asterisk.

Future Directions
miRNA Dependence
In future proposed studies, it will be necessary determine if miRNA binding and
sponging is responsible for the effect on CDKN2A seen by the reduction in CDLINC B+C. After
transcription the immature pre-miRNA must be processed to form the mature, shortened miRNA
form. This process occurs in two steps: first the DROSHA micro processing complex cuts off the
long single stranded parts and then the pre-miRNA is exported to the nucleus where it is cut into
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its final form by the DICER complex. “Knockdown” of the DICER and/or DROSHA complexes
would eliminate the ability of the cell to produce miRNAs. If miRNAs are no longer produced
then when RNAi treatment to reduce CDLINC B+C expression is used there should be no
subsequent effect on p14, p16, Rb and pRb expression. This would only hold true if the affect is
due to miRNAs. If the CDLINC-mediated effect on the CDKN2A pathway is still seen, then it
would be highly unlikely that the affect is mediated by miRNAs and other options should be
pursued. There may be other negative side effects of reducing total miRNA in the cell that
should be considered when determining if the CDKN2A pathway is involved. The use of a RNAi
non-targeting control will be necessary to see if the result is due to miRNA reduction or miRNA
reduction in addition to CDLINC RNAi interference.

p14 or p16 Protein vs RNA
While the results in this dissertation demonstrate that the protein levels of p14 and p16
are affected by “knockdown” of CDLINC B+C, it would be beneficial to also measure the
mRNA expression of p14 and p16. This will help determine if CDLINC is affecting CDKN2A at
the mRNA level or the protein level. If the theory holds true that CDLINC is sponging miRNAs
which normally downregulate a protooncogene which is responsible for the transcriptional
suppression of the tumor suppressor CDKN2A, then the mRNA levels as well as the protein
levels of CDKN2A should be reduced.

Absolute CDLINC Expression Levels
This study uses the expression levels of the various CDLINC isoforms as measured by
sequencing and qRT-PCR. It would be beneficial to this research to also determine the absolute
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levels of each of the 3 major isoforms of CDLINC. A standard curve analysis using the cDNA
synthesized for overexpression of CDLINC would be able to reveal the absolute quantities of
CDLINC B+C present in the samples. This would be useful for delineating why both isoforms
are needed together in order to produce the significant increase in proliferation and colony
formation ability seen in the overexpression studies performed. One hypothesis could be that
there is a specific necessary ratio of CDLINC B to CDLINC C for the metastatic phenotype.
Another hypothesis could be that there is a threshold ratio which must be overcome to progress
to the metastatic phenotype. This information will be importation for future studies to delineate
the exact mechanism by which CDLINC B+C promote NSCLC progression.

Determine Endogenous CDLINC Sequences
The overexpression experiments performed in this work use the published cDNA
sequences for the 3 major isoforms of CDLINC. It will be necessary to confirm the identity and
sequence of the endogenous forms of CDLINC for future work. To do this both the 3’UTR and
5’UTR should be sequenced. The 3’UTR can be targeted using Rapid Amplification of CDNA
Ends (RACE) which involves a primer that binds to the 3’ polyadenlyation sequence on cDNA
allowing for the sequencing from the 3’ end including the 3’UTR when using a second primer
further upstream in the lncRNA. Sequencing the 5’UTR may be achieved using a similar
protocol.

Function of CDLINC A
Another interesting avenue of investigation would be to determine the function of the
“basal” CDLINCa isoform. Analysis of the sequence of the CDLINC lincRNAs revealed a

59

known nuclear localization motif which is present in exon 3 of CDLINC which is only included
in the CDLINCa isoform [148]. Nuclear lncRNAs are incredibly difficult to “knockdown” via
traditional siRNA molecules [149], therefore ASO molecules were designed to not only
“knockdown” CDLINCa, but also to remove CDLINCa from the nucleus without activating the
RNAse H1 pathway. Future studies could therefore use these ASOs to analyze whether forced
cytosolic localization of the A isoform can recapitulate the phenotypes of B+C overexpression.
Indeed, when treated with an ASO designed to cover the nuclear localization motif, yet not
activate RNAse H degradation, preliminary results suggest that the localization of A to the
nucleus does not occur after treatment with this ASO and there is an increase in cytosolic
concentrations of CDLINC. Our preliminary findings indicate that there is a partial recapitulation
of the B+C expression phenotype seen in this circumstance. Hence, preliminarily, our data
suggest that it is the localization of the exon 4 sequence, not the expression of the sequence
itself, which is important to CDLINC function.
Related to this avenue would be to investigate whether genetic manipulation of the A
isoform leads to any phenotype at all. Indeed, ASOs have been designed to “knockdown” this
isoform while remaining in the nucleus. So far, our very preliminary data show that we can
decrease the concentration of the A isoform in the nucleus through ASO treatment. This
treatment also decreases the cytoplasmic levels of the A isoform, so reduction in total A isoform
expression is possible. This suggests a way to study the endogenous purpose of CDLINC.

Conclusions
Cancer is bad. This is the response that is likely to be heard when a child is asked about
cancer. The reality is that if cancer is bad, lung cancer is the worst. Not only is it the leading
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cause of cancer related deaths worldwide, it is often diagnosed in the late stages leading to a low
5-year survival rate. Discovery of novel therapeutic molecular markers is necessary moving
forward in this dynamic world of next generation technologies and ever-expanding omics.
NSCLC personalized treatments need to look beyond the protein coding genes which comprise
so little of the human genome and into the non-coding transcriptome.
We have identified one such non-coding gene, CDLINC (and Alt-CDLINC), whose
expression can be mediated using RNA interference techniques. Our findings suggest that this
novel non-coding gene pair may be a valid therapeutic target in future “personalized medicine”
regimens.
Novel lincRNAs CDLINC and Alt-CDLINC promote NSCLC progression through the
upregulation of the cytoplasmic isoforms. One hypothesis is that CDLINC and Alt-CDLINC act
as CTAs which could become oncogenic when dysregulated in non-germline cell lineages. These
lncRNAs promote proliferation of NSCLC cells in a CDKN2A mutational status dependent
fashion. Our preliminary findings also This novel lncRNA provides interesting insight into a
possible mechanism that CDKN2A positive cancer cells may be using to overcome cell cycle
checkpoint arrest.
While the precise mechanism behind CDLINC’s CDKN2A dysregulation mechanism is
unknown, our data strongly suggest that it is acting as ceRNA to sponge miRNAs thus indirectly
suppressing CDKN2A expression. Further studies to elucidate this mechanism will include
biotinylating suspected miRNAs involved in this pathway and performing streptavidin binding
pulldown with subsequent qRT-PCR identification of binding partners to confirm direct
interaction between the miRNA and CDLINC. The targetability of CDLINC by RNAi suggests it
may act as a candidate for targeted therapeutics in the future of NSCLC treatment.
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The results shown here are in part based upon data generated by the TCGA Research
Network: https://www.cancer.gov/tcga. The Genotype-Tissue Expression (GTEx) Project was
supported by the Common Fund of the Office of the Director of the National Institutes of Health,
and by NCI, NHGRI, NHLBI, NIDA, NIMH, and NINDS. The data used for the analyses
described in this manuscript were obtained from the GTEx Portal on 3/6/2020.
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APPENDIX A: DESCRIPTION OF CELL LINES USED
Table A1: Description of cell lines used
Cell Line
HBEC3KT
HBEpC
A549
H358
H460
H838
H1299
H1792
H1869
MDA231
MDA468

Tissue
Lung
Lung
Lung
Lung
Lung
Lung
Lung
Lung
Lung
Breast
Breast

Cancer Type
n/a
n/a
LUAD
LUAD
LCLC
LUAD
LUAD
LUAD
LUSC
TNBC
TNBC

ATCC Description
Immortalized primary lung bronchial epithelial cells
Primary lung epithelial cells
Carcinoma
bronchioalveolar carcinoma; non-small cell lung cancer
carcinoma; large cell lung cancer
3B, adenocarcinoma; non-small cell lung cancer
carcinoma; non-small cell lung cancer
stage 4, adenocarcinoma
squamous cell, stage 4, non-small cell lung cancer
Adenocarcinoma
Adenocarcinoma

Table A2: Updated mutational status for all cell lines used
Cell line

CDKN2A

KRAS

NRAS

TP53

PIK3CA

PTEN

RB1

SMAD4

BRAF

HBEC

wt

wt

wt

wt

Wt

wt

wt

wt

wt

H358

wt

G12C

wt

mut

wt

wt

wt

wt

wt

H1299

wt

wt

Q61K

null

wt

wt

wt

wt

wt

H1792

wt

G12C

wt

null

wt

wt

wt

wt

wt

A549

0*

G12S

wt

wt

wt

wt

wt

wt

wt

H460

*

Q61H

wt

wt

E545K

wt

wt

wt

wt

H838

0*

wt

wt

E62*

wt

wt

wt

wt

wt

H1869

*

wt

wt

mut

wt

wt

wt

wt

wt

MDA468

wt

wt

wt

R275H

wt

*

*

0*

wt

MDA231

0*

G13D

wt

R280K

wt

wt

wt

wt

G469V
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APPENDIX B: TP53 ONCOGENOTYPE TESTING

Figure A1: Confirmation of H838 p53 mutational status
Blotting of p53 protein levels in untreated and non-targeting siRNA (siNT) showed expression of
p53 protein. Samples treated with p53 targeting siRNA (sip53) and H838 cell line showed no
expression of p53 protein. The finding that H838 does not produce p53 protein is consistent with
findings that our targeted genes were not following the expected expression pattern when
measured in H460 and H460 CRISPER p53 knockout cells.

Expression

CDLINC
30
25
20
15
10
5
0

E2-5
E2-8
E3-8

Cell Line

Figure A2: CDLINC p53 expression dependence testing
CDLINC expression levels measured by qRT-PCR for CDLINC A (blue, E2-5), CDLINC B
(orange, E2-8) and CDLINC C (grey, E3-8). This expression data was used to refute the initial
hypothesis that CDLINC expression was specific to the p53 mutation oncogenotype. CDLINC
expression was not altered by reducing p53 expression either by RNAi (siCTR_A549 vs.
siP53_A549) or CRISPER knockout of p53 (H460 vs. H46_P53_KO). H838 also did not show
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altered CDLINC expression which would have been expected if the differential exon usage was
due to p53 mutational status as H838 was later confirmed to have mutant TP53.
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APPENDIX C: BIOINFORMATICS PROGRAMS AND BASE SCRIPTS USED
FastQC* run with HISAT2 and Stringtie
HISAT2* run with FastQC and Stringtie
Stringtie* run with FastQC and HISAT2
(in command line, modified from [131])
to run execute: ./rnaseq_pipeline.sh out
run this after modifying rnaseq_pipeline-config.sh
“
#!/usr/bin/env bash
usage() {
NAME=$(basename $0)
cat <<EOF
Usage:
${NAME} [output_dir]
Wrapper script for HISAT2/StringTie RNA-Seq analysis protocol.
In order to configure the pipeline options (input/output files etc.)
please copy and edit a file rnaseq_pipeline.config.sh which must be
placed in the current (working) directory where this script is being launched.
##do not edit this, edit rnaseq_pipeline.config.sh
Output directories "hisat2" and "ballgown" will be created in the
current working directory or, if provided, in the given <output_dir>
(which will be created if it does not exist).
EOF
}
OUTDIR="."
if [[ "$1" ]]; then
if [[ "$1" == "-h" || "$1" == "--help" ]]; then
usage
exit 1
fi
OUTDIR=$1
fi
## load variables
if [[ ! -f ./rnaseq_pipeline.config.sh ]]; then
usage
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echo "Error: configuration file (rnaseq_pipeline.config.sh) missing!"
exit 1
fi
source ./rnaseq_pipeline.config.sh
WRKDIR=$(pwd -P)
errprog=""
if [[ ! -x $SAMTOOLS ]]; then
errprog="samtools"
fi
if [[ ! -x $HISAT2 ]]; then
errprog="hisat2"
fi
if [[ ! -x $STRINGTIE ]]; then
errprog="stringtie"
fi
if [[ "$errprog" ]]; then
echo "ERROR: $errprog program not found, please edit the configuration script."
exit 1
fi
if [[ ! -f rnaseq_ballgown.R ]]; then
echo "ERROR: R script rnaseq_ballgown.R not found in current directory!"
exit 1
fi
#determine samtools version
newsamtools=$( ($SAMTOOLS 2>&1) | grep 'Version: 1\.')
set -e
#set -x
if [[ $OUTDIR != "." ]]; then
mkdir -p $OUTDIR
cd $OUTDIR
fi
SCRIPTARGS="$@"
ALIGNLOC=./hisat2
BALLGOWNLOC=./ballgown
LOGFILE=./run.log
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for d in "$TEMPLOC" "$ALIGNLOC" "$BALLGOWNLOC" ; do
if [ ! -d $d ]; then
mkdir -p $d
fi
done
# main script block
pipeline() {
echo [`date +"%Y-%m-%d %H:%M:%S"`] "#> START: " $0 $SCRIPTARGS
for ((i=0; i<=${#reads1[@]}-1; i++ )); do
sample="${reads1[$i]%%.*}"
sample="${sample%_*}"
stime=`date +"%Y-%m-%d %H:%M:%S"`
echo "[$stime] Processing sample: $sample"
echo [$stime] " * Alignment of reads to genome (HISAT2)"
$HISAT2 -p $NUMCPUS --dta -x ${GENOMEIDX} \
-1 ${FASTQLOC}/${reads1[$i]} \
-2 ${FASTQLOC}/${reads2[$i]} \
-S ${TEMPLOC}/${sample}.sam 2>${ALIGNLOC}/${sample}.alnstats
echo [`date +"%Y-%m-%d %H:%M:%S"`] " * Alignments conversion (SAMTools)"
if [[ "$newsamtools" ]]; then
$SAMTOOLS view -S -b ${TEMPLOC}/${sample}.sam | \
$SAMTOOLS sort -@ $NUMCPUS -o ${ALIGNLOC}/${sample}.bam else
$SAMTOOLS view -S -b ${TEMPLOC}/${sample}.sam | \
$SAMTOOLS sort -@ $NUMCPUS - ${ALIGNLOC}/${sample}
fi
#$SAMTOOLS index ${ALIGNLOC}/${sample}.bam
#$SAMTOOLS flagstat ${ALIGNLOC}/${sample}.bam
#echo "..removing intermediate files"
rm ${TEMPLOC}/${sample}.sam
#rm ${TEMPLOC}/${sample}.unsorted.bam
echo [`date +"%Y-%m-%d %H:%M:%S"`] " * Assemble transcripts (StringTie)"
$STRINGTIE -p $NUMCPUS -G ${GTFFILE} -o ${ALIGNLOC}/${sample}.gtf \
-l ${sample} ${ALIGNLOC}/${sample}.bam
done
## merge transcript file
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echo [`date +"%Y-%m-%d %H:%M:%S"`] "#> Merge all transcripts (StringTie)"
ls -1 ${ALIGNLOC}/*.gtf > ${ALIGNLOC}/mergelist.txt
$STRINGTIE --merge -p $NUMCPUS -G ${GTFFILE} \
-o ${BALLGOWNLOC}/stringtie_merged.gtf ${ALIGNLOC}/mergelist.txt
## estimate transcript abundance
echo [`date +"%Y-%m-%d %H:%M:%S"`] "#> Estimate abundance for each sample
(StringTie)"
for ((i=0; i<=${#reads1[@]}-1; i++ )); do
sample="${reads1[$i]%%.*}"
dsample="${sample%%_*}"
sample="${sample%_*}"
if [ ! -d ${BALLGOWNLOC}/${dsample} ]; then
mkdir -p ${BALLGOWNLOC}/${dsample}
fi
$STRINGTIE -e -B -p $NUMCPUS -G ${BALLGOWNLOC}/stringtie_merged.gtf \
-o ${BALLGOWNLOC}/${dsample}/${dsample}.gtf
${ALIGNLOC}/${sample}.bam
done
echo [`date +"%Y-%m-%d %H:%M:%S"`] "#> Generate the DE tables (Ballgown)"
Rscript ${WRKDIR}/rnaseq_ballgown.R ${PHENODATA}
### This should generate the DE tables in the output directory:
### GRCh38_transcripts_results.csv
### GRCh38_genes_results.csv
echo [`date +"%Y-%m-%d %H:%M:%S"`] "#> DONE."
} #pipeline end
pipeline 2>&1 | tee $LOGFILE
“
Modify this first before running the above:
“
“## Configuration file for rnaseq_pipeline.sh
##
## Place this script in a working directory and edit it accordingly.
##
## The default configuration assumes that the user unpacked the
## chrX_data.tar.gz file in the current directory, so all the input
## files can be found in a ./chrX_data sub-directory
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#how many CPUs to use on the current machine?
NUMCPUS=6
#### Program paths ####
## optional BINDIR, using it here because these programs are installed in a common
directory
#BINDIR=/usr/local/bin
#HISAT2=$BINDIR/hisat2
#STRINGTIE=$BINDIR/stringtie
#SAMTOOLS=$BINDIR/samtools
#if these programs are not in any PATH directories, please edit accordingly:
HISAT2=/media/christina/Chalfant_Lab/RNA_HOME/hisat2-2.1.0/hisat2
STRINGTIE=/media/christina/Chalfant_Lab/RNA_HOME/stringtie-1.3.4b/stringtie
SAMTOOLS=/media/christina/Chalfant_Lab/RNA_HOME/samtools-1.3.1/samtools
#### File paths for input data
### Full absolute paths are strongly recommended here.
## Warning: if using relatives paths here, these will be interpreted
## relative to the chosen output directory (which is generally the
## working directory where this script is, unless the optional <output_dir>
## parameter is provided to the main pipeline script)
## Optional base directory, if most of the input files have a common path
# BASEDIR="/home/johnq/RNAseq_protocol/chrX_data"
BASEDIR="/media/christina/Chalfant_Lab/deepseq_CJMonco/GRCh38"
FASTQLOC="$BASEDIR/samples"
GENOMEIDX="$BASEDIR/indexes/genome_tran"
GTFFILE="$BASEDIR/genes/Homo_sapiens.GRCh38.91.gtf"
PHENODATA="$BASEDIR/CJM_phenodata.csv"
TEMPLOC="./tmp" #this will be relative to the output directory
## list of samples
## (only paired reads, must follow _1.*/_2.* file naming convention)
reads1=(${FASTQLOC}, m/*_1.*)
reads1=("${reads1[@]##*/}")
reads2=("${reads1[@]/_1./_2.}")
“
Ballgown
(run in R, modified from [131])
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#!/usr/bin/env Rscript
# run this in the output directory for rnaseq_pipeline.sh
# passing the pheno data csv file as the only argument
args = commandArgs(trailingOnly=TRUE)
if (length(args)==0) {
# assume no output directory argument was given to rnaseq_pipeline.sh
pheno_data_file <- paste0(getwd(), "/GRCh38/CJM_phenodata.csv")
} else {
pheno_data_file <- args[1]
}
library(ballgown)
library(RSkittleBrewer)
library(genefilter)
library(dplyr)
library(devtools)
## Read phenotype sample data
pheno_data <- read.csv(pheno_data_file)
## Read in expression data
bg_GRCh38 <- ballgown(dataDir = "ballgown", samplePattern="CJM",
pData=pheno_data)
## Filter low abundance genes
bg_GRCh38_filt <- subset(bg_GRCh38, "rowVars(texpr(bg_GRCh38)) > 1",
genomesubset=TRUE)
## DE by transcript
results_transcripts <- stattest(bg_GRCh38_filt, feature='transcript', covariate='cell_line',
getFC=TRUE, meas='FPKM')
## DE by gene
results_genes <- stattest(bg_GRCh38_filt, feature='gene', covariate='cell_line',
getFC=TRUE, meas='FPKM')
## Add gene name
results_transcripts <- data.frame(geneNames=ballgown::geneNames(bg_GRCh38_filt),
geneIDs=ballgown::geneIDs(bg_GRCh38_filt), results_transcripts)
## Sort results from smallest p-value
results_transcripts <- arrange(results_transcripts, pval)
results_genes <- arrange(results_genes, pval)
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## Write results to CSV
write.csv(results_transcripts, "GRCh38_transcripts_results.csv", row.names=FALSE)
write.csv(results_genes, "GRCh38_genes_results.csv", row.names=FALSE)
## Filter for genes with q-val <0.05
subset(results_transcripts, results_transcripts$qval <=0.05)
subset(results_genes, results_genes$qval <=0.05)
## Plotting setup
tropical <- c('darkorange', 'dodgerblue', 'hotpink', 'limegreen', 'yellow')
palette(tropical)
## Plotting gene abundance distribution
fpkm <- texpr(bg_GRCh38, meas='FPKM')
fpkm <- log2(fpkm +1)
boxplot(fpkm, col=as.numeric(pheno_data$cell_line), las=2,ylab='log2(FPKM+1)')
## Plot individual transcripts
#ballgown::transcriptNames(bg_GRCh38)[12]
#plot(fpkm[12,] ~ pheno_data$cell_line, border=c(1,2),
# main=paste(ballgown::geneNames(bg_GRCh38)[12], ' :
#',ballgown::transcriptNames(bg_GRCh38)[12]),
# pch=19, xlab="Cell_Line", ylab='log2(FPKM+1)')
#points(fpkm[12,] ~ jitter(as.numeric(pheno_data$cell_line)),
col=as.numeric#(pheno_data$cell_line))
## Plot gene of transcript 1729
#plotTranscripts(ballgown::geneIDs(bg_GRCh38)[1729], bg_GRCh38,
#
main=c('Gene XIST in sample ERR188234'), sample=c('ERR188234'))
## Plot average expression
#plotMeans(ballgown::geneIDs(bg_GRCh38)[203], bg_GRCh38_filt,
groupvar="cell_line", legend=FALSE)
DEXSeq:
(run in R, modified from [134])
library(DEXSeq)
library(GenomicRanges)
library(GenomicFeatures)
library(GenomicAlignments)
library(biomaRt)
library(Biostrings)
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##set working directory to location of bam files or use ("/bam_file_directory",
pattern='bam$', full=TRUE)
fls = list.files (pattern='bam$', full=TRUE )
#use lower yieldSize on lower ram computers, the workstation has 256Gb, the cubes and
towers have 32GB, a good laptop has 16GB, a standard computer has 8GB
bamlst = BamFileList (fls, index=character(), yieldSize=100000, obeyQname=TRUE )
#make txdb in advance from gtf that used same naming convention as your alignment did
(ensembl .fa with ensembl .gtf)
txdb99 = loadDb("txdb99.sqlite")
#Jan 2020 update in GenomicRanges changed to exonicParts instead of disjoint.exons
ex = exonicParts(txdb99, linked.to.single.gene.only=TRUE )
#this step takes a while
SE2 = summarizeOverlaps (ex, bamlst, mode="Union", singleEnd=FALSE,
ignore.strand=TRUE, inter.feature=FALSE, fragments=TRUE )
#set the labels for your conditions based on the order of the bam files seen to the right in
the file viewer
colData(SE2)$condition = c("Mut", "Mut", "Mut", "Wt", "Wt", "Wt", "Wt", "Wt", "Mut",
"Mut", "Ctr", "Ctr")
dxd1 = DEXSeqDataSetFromSE ( SE2, design= ~ sample + exon + condition:exon )
dxd1 = estimateSizeFactors (dxd1 )
dxd1 = estimateDispersions (dxd1 )
#dxd = nbinomLRT(dxd, reduced = ~ 1, maxit=1000)
dxd1 = testForDEU (dxd1 )
dxd1 = estimateExonFoldChanges (dxd1, fitExpToVar="condition")
save(dxd1, file = "dxdcdkn2a99.RData")
dxr2 = DEXSeqResults ( dxd1 )
save(dxr2, file = "dxrcdkn2a99.RData")
write.csv(dxr2, file = "dxrcdkn2a99.csv")
#generates a full html report for all genes with differentially expressed exons by
condition and all graphs for all significant genes (takes a long time)
#DEXSeqHTML(object=dxr1)
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DEXSeqHTML(object=dxr2, FDR=0.05, color=c("#FF0000FF", "#FFFF0000",
"#FFFF00FF"))
plotDEXSeq(dxr2, "ENSG00000267605", norCounts=TRUE, displayTranscripts=TRUE,
expression=FALSE, splicing=TRUE, legend=TRUE, cex.axis=1.2, cex=1.3, lwd=2)

GTEx Portal: web browser-based software
CBioPortal: web browser-based software
GDC Data Portal: web browser-based software
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APPENDIX D: SUPPLEMENTAL FIGURES FOR CHAPTER THREE

Figure A3: RNAi-mediated depletion of p14, but not p16 was achievable
Left: Western and qPCR (n=2) for CDKN2A KD at 100nm and 48/72 hours. Right: Repeated
transfection at 100nm twice 24 hours apart; harvested at 72 hours; loaded more protein per
sample. P14 was successfully “knocked down” in both; hence likely does not regulate CDLINC
(ENSG00000267053). P16 was not successfully “knocked down” in either. CDLINC is thus not
regulated by p14, and unlikely to be regulated by p16.

91

Figure A4: Initial “knockdown” of ENSG00000267053
Initial “knockdown” testing of custom siRNAs designed to target ENSG00000267053
(Linc267053, CDLINC) harvested at either 48 or 72 hours. Transfection of H1299 cells was
performed with either non-targeting (NT) siRNA or custom siRNAs. These data were used to
determine that the A isoform was not being affected while the B and C isoforms were always
targeted together.
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Figure A5: Image of cyto-“knockdown” effect in H1299 on soft agar

Figure A6: Magnified image of cyto-“knockdown” effect in H1299 on soft agar
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Figure A7: Predicted target gene interactions with the synaptogenesis signaling pathway
Biological molecules are shaded in grey and circled in purple are involved in the synaptogenesis
signaling pathways predicted to be targeted by miRNAs from IPA (Table 8) predicted to bind to
E4 of CDLINC.
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Figure A8: Predicted target gene interactions with the tight junction signaling pathway
Biological molecules are shaded in grey and circled in purple which are involved in the tight
junction signaling pathways predicted to be targeted by those miRNAs from IPA predicted to be
targeted by miRNAs from table 8 predicted to bind to E4 of CDLINC.
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Figure A9: Predicted target gene interactions with the molecular mechanisms of cancer pathway
Biological molecules are shaded in grey and circled in purple which are involved in the
molecular mechanisms of cancer signaling pathways predicted to be targeted by those miRNAs
from IPA predicted to be targeted by miRNAs from table 8 predicted to bind to E4 of CDLINC.
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Figure 330: Cellular location of predicted target gene interactions with CDKN2A
Relationships from figure 32 showing cellular location of predicted target genes from table 8
. Biological molecules are shaded in grey and circled in purple which are involved in the
molecular mechanisms of cancer signaling pathways predicted to be targeted by those miRNAs
from IPA predicted to be targeted by miRNAs from table 8 predicted to bind to E4 of CDLINC.
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APPENDIX E: ANTISENSE OLIGONUCLOTIDE DESIGN
ENSG00000267053 Exon 5, transcript A
GTGGAAACCCCCTTCCCATGGGGTGAAGCGCAGTCTGCTCCAGAGACCCACTGTTAG
GGTCGGGGATGTCACAGAAATTAACAGGGCAGCCAATTCCCATCCAGAGGGGCCCA
GGATGACCCCGAACCCTCTAGCTCAGCCCCAAGCTCGGGCCAGGGAGTGAAGCCTT
TGTCCCCAAGCAACAGAGTGAGGGTCTGTCTCTAACCCGGTGGGCTCCAGTGAAAG
GAAAATGGCCTGGAGGTGCCCACAGGAGGGCGCCCTAGTTCTGAGACAGGTCTACG
GCTCCCAGACTGCGTCCCCATGAGTAACAGAGGGACACGCAGAGGGGCATACTGAG
TGCCTATAGGGGACTCACAGACTGCAGATGCACGCTGCGGATCCAGAAGCCGGTCA
G

Highlighted = nuclear localization motif
mN*mN*mN*mN*mN*N*N*N*N*N*N*N*N*N*N*mN*mN*mN*mN*mN*mN
m = 2-O-methyl RNA
* = phosphorothioate internucleoside linkage

ASO1: beginning, 20bp, BLAST checked
Sense:

GCTCCAGAGACCCACTGTTA

Antisense: TAACAGTGGGTCTCTGGAGC
Sense:

mG*mC*mU*mC*mC*A*G*A*G*A*C*C*C*A*C*mU*mG*mU*mU*mA

Antisense: mU*mA*mA*mC*mA*G*T*G*G*G*T*C*T*C*T*mG*mG*mA*mG*mC
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ASO2: nuclear localization motif, 20bp, BLAST checked
Sense:

CCTCTAGCTCAGCCCCAAGC

Antisense: GCTTGGGGCTGAGCTAGAGG
Sense:

mC*mC*mU*mC*mU*A*G*C*T*C*A*G*C*C*C*mC*mA*mA*mG*mC

Antisense: mG*mC*mU*mU*mG*G*G*G*C*T*G*A*G*C*T*mA*mG*mA*mG*mG
ASO3: end, 20bp, BLAST checked
Sense:

AGTAACAGAGGGACACGCAG

Antisense: CTGCGTGTCCCTCTGTTACT
Sense:

mA*mG*mU*mA*mA*C*A*G*A*G*G*G*A*C*A*mC*mG*mC*mA*mG

Antisense: mC*mU*mG*mC*mG*T*G*T*C*C*C*T*C*T*G*mU*mU*mA*mC*mU
ASO4: nuclear localization motif, 17bp, no RNAseH degradation, BLAST checked
Sense:

TCTAGCTCAGCCCCAAG

Antisense: CTTGGGGCTGAGCTAGA
Sense:

mU*C*mT*A*mG*C*mU*C*mA*G*mC*C*mC*C*mA*A*mG

Antisense: mC*T*mU*G*mG*G*mG*C*mU*G*mA*G*mC*T*mA*G*mA
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APPENDIX F: SIRNA DESIGN
Four siALL siRNAs were pooled in equal ratios for “knockdown” of CDLINC:
5’-CCACGAGAGCAUCGCGGGAUU-3’
5’-ACAAGUUUCUCCUCUGCAAUU-3’
5’-CGCCAAAGGAUUCUGGAAAUU -3’
5’-CUUAGGAGCGACUGUUAAUU-3’

Table A3: Custom and premade siRNAs from Dharmacon
Name
siCDKN2A
siCDKN2A
siA
siA
siB
siB
siC
siC
siALL
siALL
siALL
siALL
siControl
siTP53

Dharmacon Catalog #
CTM-517626
CTM-517627
CTM-509141
CTM-509142
CTM-508440
CTM-508442
CTM-508406
CTM-508407
CTM-446469
CTM-446470
CTM-446471
CTM-446472
D-001810-10-05
L-011007-00-005

Sequence
5' CGG GAG GGC UUC CUG GAC A UU 3'
5' CAC CAG AGG CAG UAA CCA U UU 3'
5' CCG GUG GGC UCC AGU GAA A UU 3'
5' GGG AUG UCA CAG AAA UUA A UU 3'
5' GCG CGG ACG GUG UGC GGC G UU 3'
5' UGC GGC GCA CAC AAC CAA GC UU 3'
5' GGA AGA AAC CUC AGA CAG A UU 3'
5' GGA AGA AAC CCC CAG GAG GA UU 3'
5' CUU AGG AGC CGA CUG UUA A UU 3'
5' ACA AGU UUC UCC UCU GCA A UU 3'
5' CGC CAA AGG AUU CUG GAA A UU 3'
5' CCA CGA GAG CAU CGC GGG GA UU 3'
ON-TARGETplus Non-targeting Control Pool
ON-TARGETplus Human CDKN2A (1029) siRNA-SMARTpool
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Target
CDKN2A E2
CDKN2A E2
CDLINC E3
CDLINC E3
CDLINC E1-4
CDLINC E1-4
CDLINC E2
CDLING E2
CDLINC E4
CDLINC E4
CDLINC E4
CDLINC E4
Non-Targeting
TP53

APPENDIX G: OVEREXPRESSION PLASMID DESIGN
Sequences used for plasmid synthesis for CDLINC A, B and C.
CDLINC A:
>ENST00000586345.6 AC092296.2-201 cdna:lncRNA “A”
ACAGTGAAAGCCACCGTTGCCCGGGGATGGGTCCCTGACACTTGGGGAAGTAGGAG
CCCTGTGTGATCGTGCGTCTGAGTCTGGGCTGAGACCAGTCCTGGCCAGGGCAGTTA
CCAGGACGGTCTCCGGAGGCCGGGATTCGCGGAGGGTCCAGCAGCAGGAAGAAAC
CCCAGGAGGAAGAAACCTCAGACAGATCGCCGGCGAGGCAGCGCGGGATCCCAGC
CTCAGGCGTGCGCGGACGGTGTGCGGGTGGAAACCCCCTTCCCATGGGGTGAAGCG
CAGTCTGCTCCAGAGACCCACTGTTAGGGTCGGGGATGTCACAGAAATTAACAGGG
CAGCCAATTCCCATCCAGAGGGGCCCAGGATGACCCCGAACCCTCTAGCTCAGCCC
CAAGCTCGGGCCAGGGAGTGAAGCCTTTGTCCCCAAGCAACAGAGTGAGGGTCTGT
CTCTAACCCGGTGGGCTCCAGTGAAAGGAAAATGGCCTGGAGGTGCCCACAGGAGG
GCGCCCTAGTTCTGAGACAGGTCTACGGCTCCCAGACTGCGTCCCCATGAGTAACAG
AGGGACACGCAGAGGGGCATACTGAGTGCCTATAGGGGACTCACAGACTGCAGATG
CACGCTGCGGATCCAGAAGCCGGTCAGCGCACACAACCAAGCTTAGGAGCCGACTG
TTAAGATGCCCCAGTGACACGGACAAGTTTCTCCTCTGCAACCCAATGAGAGCTGCT
GACCACGAGAGCATCGCGGGACCGCCAAAGGATTCTGGAAAATGTGGTCCCGGGTG
GCCAGTGTGCGCTGACCTTCACCTGAAGGTACGGCTTGAAGGAAACTTCTGGAGG
GTGGGGTGGTGTTGAAGAGAAGGCACAATTGTCACCATTTTGTTCAACATGGGCGTT
TTCTTTGTGCATTGATTTGCATTTTTAAAGGTATTCCATTAAAAATATGTTTATC
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CDLINC B:
>ENST00000586488.6 AC092296.2-202 cdna:lncRNA “B”
ACAGTGAAAGCCACCGTTGCCCGGGGATGGGTCCCTGACACTTGGGGAAGTAGGAG
CCCTGTGTGATCGTGCGTCTGAGTCTGGGCTGAGACCAGTCCTGGCCAGGGCAGTTA
CCAGGACGGTCTCCGGAGGCCGGGATTCGCGGAGGGTCCAGCAGCAGGAAGAAAC
CCCAGGAGGAAGAAACCTCAGACAGATCGCCGGCGAGGCAGCGCGGGATCCCAGC
CTCAGGCGTGCGCGGACGGTGTGCGGCGCACACAACCAAGCTTAGGAGCCGACTGT
TAAGATGCCCCAGTGACACGGACAAGTTTCTCCTCTGCAACCCAATGAGAGCTGCTG
ACCACGAGAGCATCGCGGGACCGCCAAAGGATTCTGGAAAATGTGGTCCCGGGTGG
CCAGTGTGCGCTGACCTTCACCTGAAGGTACGGCTTGAAGGAAACTTCTGGAGGGTG
GGGTGGTGTTGAAGAGAAGGCACAATTGTCACCATTTTGTTCAACATGGGCGTTTTC
TTTGTGCATTGATTTGCATTTTTAAAGGTATTCCATTAAAAATATGTTTATCTATTTTA
A
CDLINC C:
>ENST00000590845.1 AC092296.2-203 cdna:lncRNA “C”
CGGTCTCCGGAGGCCGGGATTCGCGGAGGGTCCAGCAGCAGGAAGAAACCCCAGG
AGGAAGAAACCTCAGACAGATCGCCGGCGAGGCAGCGCGGGATCCCAGCCTCAGG
CGTGCGCGGACGGTGTGCGGCGCACACAACCAAGCTTAGGAGCCGACTGTTAAGAT
GCCCCAGTGACACGGACAAGTTTCTCCTCTGCAACCCAATGAGAGCTGCTGACCACG
AGAGCATCGCGGGACCGCCAAAGGATTCTGGAAAATGTGGTCCCGGGTGGCCAGTG
TGCGCTGACCTTCACCTGAAGGTACGGCTTGAAGGAAACTTCTGGAGGGTGGGGTG
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GTGTTGAAGAGAAGGCACAATTGTCACCATTTTGTTCAACATGGGCGTTTTCTTTGT
GCATTGATTTGCATTTTTAAAGGTATTCCATTAAAAATATGTTTATC

Validated plasmid sequences after shifting cDNA from shuttle vector to pcDNA 3.1+ vector:
Sites where the restriction enzymes directionally inserted each CDLINC cDNA are in blue.
Confirmed CDLINC cDNA sequences are in yellow.
CDLINC A
>19ACWNPP_2667641 “A”
CACTATAGGGCGAATTGAAGGAAGGCCGTCAAGGCCGCATACAGTGAAAGCCACCG
TTGCCCGGGGATGGGTCCCTGACACTTGGGGAAGTAGGAGCCCTGTGTGATCGTGCG
TCTGAGTCTGGGCTGAGACCAGTCCTGGCCAGGGCAGTTACCAGGACGGTCTCCGG
AGGCCGGGATTCGCGGAGGGTCCAGCAGCAGGAAGAAACCCCAGGAGGAAGAAAC
CTCAGACAGATCGCCGGCGAGGCAGCGCGGGATCCCAGCCTCAGGCGTGCGCGGAC
GGTGTGCGGGTGGAAACCCCCTTCCCATGGGGTGAAGCGCAGTCTGCTCCAGAGAC
CCACTGTTAGGGTCGGGGATGTCACAGAAATTAACAGGGCAGCCAATTCCCATCCA
GAGGGGCCCAGGATGACCCCGAACCCTCTAGCTCAGCCCCAAGCTCGGGCCAGGGA
GTGAAGCCTTTGTCCCCAAGCAACAGAGTGAGGGTCTGTCTCTAACCCGGTGGGCTC
CAGTGAAAGGAAAATGGCCTGGAGGTGCCCACAGGAGGGCGCCCTAGTTCTGAGAC
AGGTCTACGGCTCCCAGACTGCGTCCCCATGAGTAACAGAGGGACACGCAGAGGGG
CATACTGAGTGCCTATAGGGGACTCACAGACTGCAGATGCACGCTGCGGATCCAGA
AGCCGGTCAGCGCACACAACCAAGCTTAGGAGCCGACTGTTAAGATGCCCCAGTGA
CACGGACAAGTTTCTCCTCTGCAACCCAATGAGAGCTGCTGACCACGAGAGCATCG
CGGGACCGCCAAAGGATTCTGGAAAATGTGGTCCCGGGTGGCCAGTGTGCGCTGAC
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CTTCACCTGAAGGTACGGCTTGAAGGAAACTTCTGGAGGGTGGGGTGGTGTTGAAG
AGAAGGCACAATTGTCACCATTTTGTTCAACATGGGCGTTTTCTTTGTGCATTGATTT
GCATTTTTAAAGGTATTCCATTAAAAATATGTTTATCCTGGGCCTCATGGGCCTTCCT
TTCACTGCCCGCTTTCCAG
CDLINC B
>19ACWNOP_2667640 “B”
CACTATAGGGCGAATTGAAGGAAGGCCGTCAAGGCCGCATACAGTGAAAGCCACCG
TTGCCCGGGGATGGGTCCCTGACACTTGGGGAAGTAGGAGCCCTGTGTGATCGTGCG
TCTGAGTCTGGGCTGAGACCAGTCCTGGCCAGGGCAGTTACCAGGACGGTCTCCGG
AGGCCGGGATTCGCGGAGGGTCCAGCAGCAGGAAGAAACCCCAGGAGGAAGAAAC
CTCAGACAGATCGCCGGCGAGGCAGCGCGGGATCCCAGCCTCAGGCGTGCGCGGAC
GGTGTGCGGCGCACACAACCAAGCTTAGGAGCCGACTGTTAAGATGCCCCAGTGAC
ACGGACAAGTTTCTCCTCTGCAACCCAATGAGAGCTGCTGACCACGAGAGCATCGC
GGGACCGCCAAAGGATTCTGGAAAATGTGGTCCCGGGTGGCCAGTGTGCGCTGACC
TTCACCTGAAGGTACGGCTTGAAGGAAACTTCTGGAGGGTGGGGTGGTGTTGAAGA
GAAGGCACAATTGTCACCATTTTGTTCAACATGGGCGTTTTCTTTGTGCATTGATTTG
CATTTTTAAAGGTATTCCATTAAAAATATGTTTATCTATTTTAACTGGGCCTCATGGG
CCTTCCTTTCACTGCCCGCTTTCCAG
CDLINC C
>19ACWNNP_2667639 “C”
CACTATAGGGCGAATTGAAGGAAGGCCGTCAAGGCCGCATCGGTCTCCGGAGGCCG
GGATTCGCGGAGGGTCCAGCAGCAGGAAGAAACCCCAGGAGGAAGAAACCTCAGA
CAGATCGCCGGCGAGGCAGCGCGGGATCCCAGCCTCAGGCGTGCGCGGACGGTGTG
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CGGCGCACACAACCAAGCTTAGGAGCCGACTGTTAAGATGCCCCAGTGACACGGAC
AAGTTTCTCCTCTGCAACCCAATGAGAGCTGCTGACCACGAGAGCATCGCGGGACC
GCCAAAGGATTCTGGAAAATGTGGTCCCGGGTGGCCAGTGTGCGCTGACCTTCACCT
GAAGGTACGGCTTGAAGGAAACTTCTGGAGGGTGGGGTGGTGTTGAAGAGAAGGCA
CAATTGTCACCATTTTGTTCAACATGGGCGTTTTCTTTGTGCATTGATTTGCATTTTTA
AAGGTATTCCATTAAAAATATGTTTATCCTGGGCCTCATGGGCCTTCCTTTCACTGCC
CGCTTTCCAG
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